eosinophilic pneumonia: An inflammatory lung disorder characterized by an increased number of eosinophils in the lungs. The majority of cases are idiopathic, without identifiable cause. In a minority of cases, medications, fungal infections, and environmental triggers have been implicated. It manifests as acute or chronic. Acute eosinophilic pneumonia is a severe and rapidly progressing pneumonia that may lead to respiratory failure requiring mechanical ventilation. Chronic eosinophilic pneumonia follows a slower course and manifests as fever, dyspnea, cough, and weight loss.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519870 |
1. Apply sex-specific ruleNone |
519870 |
2. Check conditionsNone |
519870 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
447 |
4. Check minimum number of eventsNone |
447 |
5. Include endpointsNone |
447 |
6. Filter based on genotype QC (FinnGen only) |
436 |
Control definitions (FinnGen only)
- Control exclude
- J10_INTERSTITIUM
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- J80-J84
- Name in latin
- Eosinophilia pulmonum non alibi classificata
Similar endpoints
↥List of similar endpoints to
Pulmonary eosinophilia, not elsewhere classified
based on the number of shared cases.
Similar with more cases:
- Respiratory diseases principally affecting the interstitium, IBD co-morbidites
- Other respiratory diseases principally affecting the interstitium
- Diagnoses used for exclusion with ILD
- Diseases of the respiratory system
- Any event in hilmo or specialist outpatient
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 3168 | 1780 | 1353 |
| Only index persons | 2462 | 1464 | 998 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.05 | 0.05 | 0.04 |
| Only index persons | 0.05 | 0.05 | 0.04 |
| Median age at first event (years) | |||
| Whole population | 59.21 | 58.03 | 60.60 |
| Only index persons | 56.56 | 55.95 | 57.46 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 436 | 244 | 192 |
| Unadjusted period prevalence (%) | 0.09 | 0.09 | 0.09 |
| Median age at first event (years) | 57.90 | 54.33 | 62.44 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 447
- Matched controls
- 4470
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
J82
ICD-10 Finland
Pulmonary eosinophilia, not elsewhere classified
+∞
307.7
393
*
TGC00
NOMESCO Finland
Bronchial lavation
32.7
148.3
100
39
UGC12
NOMESCO Finland
Flexible bronchoscopy
12.2
127.2
155
187
GD1DD
NOMESCO Finland
High resolution CT examination of lungs
15.2
111.7
109
93
J45.1
ICD-10 Finland
Nonallergic asthma
11.3
111.5
139
171
H02AB06
ATC
prednisolone; systemic
14.5
100.7
400
1656
J45.0
ICD-10 Finland
Predominantly allergic asthma
9.5
97.1
139
202
203
Kela drug reimbursment
Chronic asthma and similar chronic obstructive pulmonary diseases
7.1
95.6
229
576
R91
ICD-10 Finland
Abnormal findings on diagnostic imaging of lung
8.0
90.9
159
289
J45.9
ICD-10 Finland
Asthma, unspecified
6.4
83.4
216
573
J18.9
ICD-10 Finland
Pneumonia, unspecified
6.3
83.0
272
889
R03DC03
ATC
montelukast; oral
5.4
60.0
162
429
NK6QA
NOMESCO Finland
Measurement of bone density from two or more locations with X-ray
7.1
55.5
95
163
J15.9
ICD-10 Finland
Bacterial pneumonia, unspecified
6.0
54.2
114
240
J84.9
ICD-10 Finland
Interstitial pulmonary disease, unspecified
+∞
52.1
49
*
J33.0
ICD-10 Finland
Polyp of nasal cavity
10.7
51.8
60
64
R03AK08
ATC
formoterol and beclometasone; inhalant
8.7
49.8
68
90
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
4.1
47.1
273
1238
J01MA14
ATC
moxifloxacin; systemic
5.4
46.4
108
247
DM1AA
NOMESCO Finland
Paranasal sinuses X-ray examination without contrast
9.9
45.9
56
64
5183A
ICD-9 Finland
Other diseases of lung, Pulmonary eosinophilia
+∞
44.5
42
*
R03AK06
ATC
salmeterol and fluticasone; inhalant
4.4
44.2
144
432
J84.8
ICD-10 Finland
Other specified interstitial pulmonary diseases
+∞
43.4
41
*
DM1QA
NOMESCO Finland
Paranasal sinuses X-ray examination in one projection
7.6
43.3
66
99
R03BA02
ATC
budesonide; inhalant
4.1
41.5
159
534
M05BA04
ATC
alendronic acid; oral
5.0
41.3
106
262
L04AX01
ATC
azathioprine; systemic
9.4
41.2
52
62
D72.1
ICD-10 Finland
Eosinophilia
63.8
40.1
46
8
R03AC02
ATC
salbutamol; inhalant
4.0
38.2
333
1885
DMB20
NOMESCO Finland
Functional endoscopic opening of maxillary antrum
6.7
38.1
66
113
GD1ED
NOMESCO Finland
Extensive high resolution CT examination of lungs
9.7
37.8
46
52
J46
ICD-10 Finland
Status asthmaticus
9.6
37.3
46
53
R03BA08
ATC
ciclesonide; inhalant
5.1
36.3
88
206
R03DA04
ATC
theophylline; systemic, rectal
5.8
35.5
71
140
TDM10
NOMESCO Finland
Puncture of maxillary antrum
7.6
34.7
52
76
R03BA01
ATC
beclometasone; inhalant
4.0
34.7
123
386
51920
ICD-8 Finland
Other diseases of respiratory system, Infiltratio pulmonis eosinophilica
+∞
33.8
32
*
R03AC13
ATC
formoterol; inhalant
5.9
33.3
65
125
H02AB04
ATC
methylprednisolone; systemic
3.9
33.0
121
387
49300
ICD-8 Finland
Asthma, bronchiale
9.5
32.4
40
46
J32.0
ICD-10 Finland
Chronic maxillary sinusitis
5.0
32.1
77
178
R03BB04
ATC
tiotropium bromide; inhalant
4.2
32.0
102
295
XG412
NOMESCO Finland
Flow-volume spirometry with bronchospasmolysis
6.0
31.6
60
112
J33.8
ICD-10 Finland
Other polyp of sinus
10.0
31.3
37
40
XG410
NOMESCO Finland
Flow-volume spirometry
7.3
31.2
48
72
J45.8
ICD-10 Finland
Mixed asthma
7.9
30.6
44
61
GD1AA
NOMESCO Finland
Thorax X-ray examination
3.2
30.3
302
1749
J84.1
ICD-10 Finland
Other interstitial pulmonary diseases with fibrosis
323.2
30.2
30
*
R03AK07
ATC
formoterol and budesonide; inhalant
3.2
27.3
142
562
R03BA05
ATC
fluticasone; inhalant
3.3
27.0
132
503
H02AB07
ATC
prednisone; oral
3.5
26.3
113
397
J47
ICD-10 Finland
Bronchiectasis
9.7
25.9
31
34
DNB20
NOMESCO Finland
Endoscopic ethmoidectomy
8.4
25.9
35
45
J01FA06
ATC
roxithromycin; oral
2.8
25.8
243
1323
R03AC12
ATC
salmeterol; inhalant
5.3
25.8
56
118
R01AD05
ATC
budesonide; nasal
4.5
25.7
70
178
DM1AD
NOMESCO Finland
CT of paranasal sinuses and face area
7.0
25.2
40
62
J45
ICD-10 Finland
Asthma
3.9
24.3
82
244
J01MA12
ATC
levofloxacin; systemic
3.1
23.9
135
555
R03AK11
ATC
formoterol and fluticasone; inhalant
7.8
22.3
32
44
R03AK10
ATC
vilanterol and fluticasone furoate; inhalant
4.9
21.1
49
109
H02AB09
ATC
hydrocortisone; systemic
7.8
21.0
30
41
GCA98
NOMESCO Finland
Other bronchoscopic procedure on bronchus
39.3
21.0
26
7
GD1AD
NOMESCO Finland
Thorax CT examination
4.1
20.1
59
158
A02BC02
ATC
pantoprazole; systemic
3.0
19.8
356
2541
R03AC03
ATC
terbutaline; inhalant
3.2
19.7
94
347
R01AD09
ATC
mometasone; nasal
2.4
19.1
241
1446
R01AD08
ATC
fluticasone; nasal
2.6
19.0
164
826
XG470
NOMESCO Finland
Measurement of diffusion capastity of the lungs
6.6
18.7
31
50
J32.4
ICD-10 Finland
Chronic pansinusitis
16.0
18.7
30
20
UDH02
NOMESCO Finland
Rhinopharyngoscopy
3.8
17.4
58
170
R03AL09
ATC
formoterol, glycopyrronium bromide and beclometasone; inhalant
5.2
16.9
36
74
M30.1
ICD-10 Finland
Polyarteritis with lung involvement [Churg-Strauss]
93.6
16.7
18
*
R96
ICPC
Asthma
3.1
16.3
75
270
J01CR02
ATC
amoxicillin and beta-lactamase inhibitor; systemic
2.3
16.0
264
1729
J31.0
ICD-10 Finland
Chronic rhinitis
3.6
15.9
58
180
DM1AI
NOMESCO Finland
Cone beam CT of paranasal sinus
5.9
14.8
27
48
J01FA15
ATC
telithromycin; oral
3.2
14.8
63
216
M05BA07
ATC
risedronic acid; oral
4.7
14.0
33
74
J01FA10
ATC
azithromycin; systemic
2.2
13.7
271
1863
GD1BD
NOMESCO Finland
Thorax extensive CT-examination
3.7
13.6
45
131
R06AE07
ATC
cetirizine; oral
2.1
13.1
209
1317
M81.4
ICD-10 Finland
Drug-induced osteoporosis
29.4
13.0
17
6
WW200
NOMESCO Finland
Immunization
5.8
13.0
24
43
Z01.8
ICD-10 Finland
Other specified special examinations
2.3
13.0
129
674
R06.0
ICD-10 Finland
Dyspnoea
2.2
12.8
161
925
DHB20
NOMESCO Finland
Polypectomy of internal nose
10.1
12.4
24
25
R81
ICPC
Pneumonia
4.2
12.0
33
84
S81.8
ICD-10 Finland
Open wound of other parts of lower leg
4.5
11.9
30
71
GD1CD
NOMESCO Finland
Thorax extensive CT-examination
19.6
11.7
17
9
FB1BD
NOMESCO Finland
Extensive CT examination of arteria pulmonalis
3.0
11.5
53
190
J20.9
ICD-10 Finland
Acute bronchitis, unspecified
2.2
11.4
115
601
XG474
NOMESCO Finland
Exhalation nntrogen oxide
4.8
11.3
26
57
J01.0
ICD-10 Finland
Acute maxillary sinusitis
2.1
11.0
125
684
J01FA09
ATC
clarithromycin; systemic
2.0
10.9
157
940
R06.2
ICD-10 Finland
Wheezing
3.7
10.8
35
100
Z3231
NOMESCO Finland
Registered nurse
2.1
10.8
148
869
GX1L5
NOMESCO Finland
Exhaled nitric oxide analysis
18.4
10.8
16
9
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
2.3
10.7
98
492
J22
ICD-10 Finland
Unspecified acute lower respiratory infection
3.2
10.6
45
153
M05BB03
ATC
alendronic acid and colecalciferol; oral
5.0
10.6
23
48
DPA30
NOMESCO Finland
Sphenotomy
14.7
10.6
17
12
R03DX09
ATC
mepolizumab; parenteral
+∞
10.5
10
*
R01AD12
ATC
fluticasone furoate; nasal
2.0
10.4
142
830
TGD04
NOMESCO Finland
Needle biopsy of the lungs in bronchoscopy
33.4
10.4
13
*
R05
ICD-10 Finland
Cough
2.1
10.3
115
623
R03DC01
ATC
zafirlukast; oral
7.8
10.3
23
31
R06AX27
ATC
desloratadine; oral
2.1
10.1
129
735
R01AD01
ATC
beclometasone; nasal
2.3
10.1
86
418
R02
ICPC
Shortness of breath/dyspnoea
2.3
9.9
83
400
XQ800
NOMESCO Finland
Prick test
3.1
9.7
43
150
J01AA02
ATC
doxycycline; systemic
2.2
9.7
368
3022
L04AA06
ATC
mycophenolic acid; systemic
8.7
9.7
20
24
297, ,
Kela drug reimbursment
+∞
9.4
9
*
J01MA02
ATC
ciprofloxacin; systemic
1.9
9.3
198
1337
J01CA04
ATC
amoxicillin; systemic
2.2
9.3
365
3006
R03BB01
ATC
ipratropium bromide; inhalant
3.3
9.2
36
117
E27.3
ICD-10 Finland
Drug-induced adrenocortical insufficiency
19.1
9.0
13
7
4859X
ICD-9 Finland
Bronchopneumonia, organism unspecified[PNEUMONIA NUD]
7.1
8.9
21
31
R01BA52
ATC
pseudoephedrine, combinations; oral
1.9
8.9
147
910
1240
FHL
Bronchoscopy
8.2
8.9
19
24
202
Kela drug reimbursment
Connective tissue diseases, rheumatoid arthritis and comparable disease
2.5
8.9
62
274
FM1AE
NOMESCO Finland
Standard cardiac ultrasound examination
2.1
8.9
103
563
4930A
ICD-9 Finland
Asthma, Extrinsic asthma[EXTRINSIC ASTHMA SINE EXACERBATIONE]
14.4
8.7
14
10
A02BC01
ATC
omeprazole; systemic
1.9
8.5
145
905
3028
Kela drug reimbursment
Mepolizumab
91.7
8.4
9
*
P01BA02
ATC
hydroxychloroquine; oral
2.6
8.1
49
202
M81.9
ICD-10 Finland
Osteoporosis, unspecified
3.1
8.1
34
115
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
2.2
8.1
72
355
A07AA02
ATC
nystatin; oral
2.8
7.8
39
146
3027
Kela drug reimbursment
Benralizumab
45.8
7.7
9
*
R03DX10
ATC
benralizumab; systemic
45.8
7.7
9
*
251, ,
Kela drug reimbursment
45.8
7.7
9
*
J96.1
ICD-10 Finland
Chronic respiratory failure
4.6
7.7
18
40
J02AC03
ATC
voriconazole; systemic
25.5
7.6
10
*
DPA25
NOMESCO Finland
Trephine of frontal sinus through nose
10.3
7.6
14
14
J90
ICD-10 Finland
Pleural effusion, not elsewhere classified
3.3
7.5
29
93
Z3226
NOMESCO Finland
Physiotherapist
2.0
7.5
95
535
R01AD58
ATC
fluticasone, combinations; nasal
1.9
7.5
107
628
R06AX26
ATC
fexofenadine; oral
2.8
7.4
37
139
127
Kela drug reimbursment
Transplant complication
9.6
7.3
14
15
J84.0
ICD-10 Finland
Alveolar and parietoalveolar conditions
+∞
7.3
7
*
ZXA10
NOMESCO Finland
Bilateral
1.9
7.2
100
580
J01EE01
ATC
sulfamethoxazole and trimethoprim; systemic
2.9
7.2
35
129
ZX120
NOMESCO Finland
Intravenous
2.3
7.1
57
268
J01DA06
ATC
[U] cefuroxime
2.1
7.0
77
411
50301
ICD-8 Finland
Chronic sinusitis, Maxillaris NUD
7.7
7.0
15
20
A01AB04
ATC
amphotericin B; local oral
2.8
6.9
34
126
ZXE00
NOMESCO Finland
One hour or less
1.7
6.8
172
1192
E0000UV, ,
ATC
1.7
6.8
190
1353
ZX109
NOMESCO Finland
Instruction on medicine inhalation technique
9.5
6.8
13
14
J32.9
ICD-10 Finland
Chronic sinusitis, unspecified
9.5
6.8
13
14
B44.1
ICD-10 Finland
Other pulmonary aspergillosis
40.7
6.8
8
*
4931B
ICD-9 Finland
Asthma, Intrinsic asthma[INTRINSIC ASTHMA CUM EXACERBATIONE]
17.0
6.8
10
6
4939X
ICD-9 Finland
Asthma, unspecified[ASTHMA BRONCHIALE NUD]
6.6
6.7
16
25
R04.2
ICD-10 Finland
Haemoptysis
3.5
6.6
23
69
4930B
ICD-9 Finland
Asthma, Extrinsic asthma[EXTRINSIC ASTHMA CUM EXACERBATIONE]
10.2
6.6
12
12
Z2221
NOMESCO Finland
Medical doctor
1.8
6.5
126
808
M05BX04
ATC
denosumab; parenteral
2.6
6.5
39
161
Z94.2
ICD-10 Finland
Lung transplant status
70.8
6.4
7
*
WZC30
NOMESCO Finland
Teaching
1.9
6.4
84
478
WX700
NOMESCO Finland
Respiratory and circulatory monitoring
2.0
6.3
80
448
N17.9
ICD-10 Finland
Acute renal failure, unspecified
3.0
6.3
27
93
A02BC05
ATC
esomeprazole; systemic
1.7
6.3
190
1377
J20
ICD-10 Finland
Acute bronchitis
2.2
6.3
56
276
GDA11
NOMESCO Finland
Thoracoscopic biopsy of lung
27.1
6.2
8
*
Z03.89
ICD-10 Finland
Observation for other suspected diseases and conditions
2.0
6.2
69
369
R03AL02
ATC
salbutamol and ipratropium bromide; inhalant
6.4
6.2
15
24
XF400
NOMESCO Finland
ECG with 12 standard connections
1.9
6.1
79
446
R50.9
ICD-10 Finland
Fever, unspecified
2.0
6.1
77
431
5BA08, ,
NOMESCO Finland
12.7
6.1
10
8
WX872
NOMESCO Finland
Intensive care
2.8
6.1
30
112
J06.9
ICD-10 Finland
Acute upper respiratory infection, unspecified
1.6
6.0
195
1432
L04AD01
ATC
ciclosporin; systemic
6.2
6.0
15
25
TimeCodeWAS
↥TODO / Current known limitations:
- Only showing the top 300 codes, because showing all (sometimes 20k) makes the page too slow.
- Legend / how to read the glyphs.
- Show details (e.g. Fisher or Chi-square test, LR+, etc.) when clicking on a row.
- Explanation on the underlying data / how the TimeCodeWAS is done (e.g. matched cases / controls, eligibility).
- Download CSV.
- No filters and sorters.
- Limited amount of endpoints (~400) having TimeCodeWAS data.
- Cross-links to Risteys lab test pages for lab test codes.
OMOP concept
ln(OR)
%cases with code / %controls with code
2×2 table
Pulmonary Disease
29 [38004472]
29 [38004472]
1.5e+00
3.0e+00
4.1e+00
—
5.3e+00
4.3e+00
3.1e+00
cases:24.58%
controls:6.72%
cases:42.24%
controls:3.45%
cases:28.16%
controls:0.62%
—
—
cases:41.53%
controls:0.36%
cases:73.51%
controls:3.63%
cases:67.83%
controls:8.85%
103
281
316
3898
177
144
242
4035
118
26
301
4153
—
174
15
245
4160
297
149
107
3960
253
334
120
3441
prednisolone; oral, parenteral
H02AB06 [21602734]
H02AB06 [21602734]
1.6e+00
2.5e+00
3.5e+00
—
5.0e+00
3.5e+00
2.5e+00
cases:27.92%
controls:7.56%
cases:34.13%
controls:3.90%
cases:16.23%
controls:0.57%
—
—
cases:45.82%
controls:0.57%
cases:58.42%
controls:3.92%
cases:57.37%
controls:9.72%
117
316
302
3863
143
163
276
4016
68
24
351
4155
—
192
24
227
4151
236
161
168
3948
214
367
159
3408
prednisolone
A07EA01 [21600653]
A07EA01 [21600653]
1.6e+00
2.5e+00
3.5e+00
—
5.0e+00
3.5e+00
2.5e+00
cases:27.92%
controls:7.59%
cases:34.13%
controls:3.97%
cases:16.23%
controls:0.57%
—
—
cases:45.82%
controls:0.57%
cases:58.42%
controls:3.92%
cases:57.37%
controls:9.72%
117
317
302
3862
143
166
276
4013
68
24
351
4155
—
192
24
227
4151
236
161
168
3948
214
367
159
3408
Asthma, unspecified
J45.9 [45562456]
J45.9 [45562456]
1.6e+00
2.5e+00
3.4e+00
1.0e+50
3.2e+00
2.7e+00
1.9e+00
cases:9.55%
controls:2.03%
cases:10.26%
controls:0.89%
cases:5.01%
controls:0.17%
cases:5.73%
controls:0.00%
cases:4.53%
controls:0.19%
cases:15.10%
controls:1.19%
cases:20.64%
controls:3.60%
40
85
379
4094
43
37
376
4142
21
7
398
4172
24
0
395
4179
19
8
400
4167
61
49
343
4060
77
136
296
3639
Inpatient Hospital
21 [8717]
21 [8717]
5.0e-01
1.4e+00
2.7e+00
6.1e+00
2.0e+00
1.0e+00
8.1e-01
cases:39.86%
controls:28.62%
cases:31.98%
controls:10.53%
cases:19.57%
controls:1.68%
cases:35.80%
controls:0.12%
cases:11.69%
controls:1.68%
cases:25.99%
controls:11.22%
cases:47.18%
controls:28.37%
167
1196
252
2983
134
440
285
3739
82
70
337
4109
150
5
269
4174
49
70
370
4105
105
461
299
3648
176
1071
197
2704
Thorax X-ray examination
GD1AA [2001303617]
GD1AA [2001303617]
7.6e-01
1.8e+00
3.7e+00
—
3.4e+00
2.7e+00
1.9e+00
cases:10.50%
controls:5.22%
cases:11.22%
controls:1.96%
cases:8.83%
controls:0.24%
—
—
cases:7.40%
controls:0.26%
cases:24.75%
controls:2.14%
cases:31.90%
controls:6.73%
44
218
375
3961
47
82
372
4097
37
10
382
4169
—
31
11
388
4164
100
88
304
4021
119
254
254
3521
Outpatient Visit
OP [9202]
OP [9202]
5.3e-01
9.0e-01
1.5e+00
5.5e+00
2.0e+00
1.8e+00
1.4e+00
cases:69.93%
controls:57.81%
cases:61.34%
controls:39.15%
cases:29.36%
controls:8.21%
cases:43.20%
controls:0.31%
cases:41.77%
controls:8.81%
cases:79.95%
controls:39.72%
cases:90.08%
controls:68.72%
293
2416
126
1763
257
1636
162
2543
123
343
296
3836
181
13
238
4166
175
368
244
3807
323
1632
81
2477
336
2594
37
1181
FEV1
20150-9 [3024653]
20150-9 [3024653]
2.1e+00
3.2e+00
—
1.0e+50
—
4.1e+00
3.8e+00
cases:7.40%
controls:0.98%
cases:6.68%
controls:0.29%
—
—
cases:1.19%
controls:0.00%
—
—
cases:11.88%
controls:0.22%
cases:18.23%
controls:0.48%
31
41
388
4138
28
12
391
4167
—
5
0
414
4179
—
48
9
356
4100
68
18
305
3757
Forced vital capacity [Volume] Respiratory system
19870-5 [3020158]
19870-5 [3020158]
2.1e+00
3.2e+00
—
1.0e+50
—
4.1e+00
3.8e+00
cases:7.40%
controls:0.98%
cases:6.68%
controls:0.29%
—
—
cases:1.19%
controls:0.00%
—
—
cases:11.88%
controls:0.22%
cases:18.23%
controls:0.48%
31
41
388
4138
28
12
391
4167
—
5
0
414
4179
—
48
9
356
4100
68
18
305
3757
FEV1/FVC
19926-5 [3011505]
19926-5 [3011505]
2.1e+00
3.2e+00
—
1.0e+50
—
4.1e+00
3.8e+00
cases:7.40%
controls:0.98%
cases:6.68%
controls:0.29%
—
—
cases:1.19%
controls:0.00%
—
—
cases:11.88%
controls:0.22%
cases:18.23%
controls:0.48%
31
41
388
4138
28
12
391
4167
—
5
0
414
4179
—
48
9
356
4100
68
18
305
3757
Nonallergic asthma
J45.1 [45557625]
J45.1 [45557625]
1.9e+00
3.8e+00
—
—
—
4.1e+00
3.3e+00
cases:6.21%
controls:0.96%
cases:8.59%
controls:0.22%
—
—
—
—
—
—
cases:15.10%
controls:0.29%
cases:19.30%
controls:0.87%
26
40
393
4139
36
9
383
4170
—
—
—
61
12
343
4097
72
33
301
3742
montelukast; oral
R03DC03 [21603356]
R03DC03 [21603356]
2.1e+00
2.2e+00
2.6e+00
—
2.3e+00
2.2e+00
1.7e+00
cases:12.65%
controls:1.77%
cases:10.02%
controls:1.22%
cases:3.58%
controls:0.29%
—
—
cases:1.91%
controls:0.19%
cases:9.41%
controls:1.19%
cases:14.21%
controls:2.83%
53
74
366
4105
42
51
377
4128
15
12
404
4167
—
8
8
411
4167
38
49
366
4060
53
107
320
3668
Forced vital capacity [Volume] Respiratory system --post bronchodilation
19875-4 [3001668]
19875-4 [3001668]
2.1e+00
3.3e+00
—
—
—
3.9e+00
3.6e+00
cases:6.68%
controls:0.89%
cases:6.21%
controls:0.24%
—
—
—
—
—
—
cases:9.16%
controls:0.19%
cases:13.94%
controls:0.45%
28
37
391
4142
26
10
393
4169
—
—
—
37
8
367
4101
52
17
321
3758
FEV1/FVC --post bronchodilation
69970-2 [42868459]
69970-2 [42868459]
2.1e+00
3.3e+00
—
—
—
3.9e+00
3.6e+00
cases:6.68%
controls:0.89%
cases:6.21%
controls:0.24%
—
—
—
—
—
—
cases:9.16%
controls:0.19%
cases:13.94%
controls:0.45%
28
37
391
4142
26
10
393
4169
—
—
—
37
8
367
4101
52
17
321
3758
FVC percent change Respiratory system
69982-7 [42868471]
69982-7 [42868471]
2.1e+00
3.3e+00
—
—
—
3.9e+00
3.6e+00
cases:6.68%
controls:0.89%
cases:6.21%
controls:0.24%
—
—
—
—
—
—
cases:9.16%
controls:0.19%
cases:13.94%
controls:0.45%
28
37
391
4142
26
10
393
4169
—
—
—
37
8
367
4101
52
17
321
3758
FEV1 --post bronchodilation
20155-8 [3023550]
20155-8 [3023550]
2.1e+00
3.3e+00
—
—
—
3.9e+00
3.6e+00
cases:6.68%
controls:0.89%
cases:6.21%
controls:0.24%
—
—
—
—
—
—
cases:9.16%
controls:0.19%
cases:13.94%
controls:0.45%
28
37
391
4142
26
10
393
4169
—
—
—
37
8
367
4101
52
17
321
3758
FEV1 percent change
69983-5 [42868472]
69983-5 [42868472]
2.1e+00
3.3e+00
—
—
—
3.9e+00
3.6e+00
cases:6.68%
controls:0.89%
cases:6.21%
controls:0.24%
—
—
—
—
—
—
cases:9.16%
controls:0.19%
cases:13.94%
controls:0.45%
28
37
391
4142
26
10
393
4169
—
—
—
37
8
367
4101
52
17
321
3758
Eosinophils [#/volume] in Blood
26449-9 [3013115]
26449-9 [3013115]
7.7e-01
1.5e+00
3.4e+00
1.0e+50
3.3e+00
2.1e+00
1.4e+00
cases:9.31%
controls:4.55%
cases:12.17%
controls:2.99%
cases:13.60%
controls:0.53%
cases:5.25%
controls:0.00%
cases:14.80%
controls:0.65%
cases:22.03%
controls:3.43%
cases:27.88%
controls:8.74%
39
190
380
3989
51
125
368
4054
57
22
362
4157
22
0
397
4179
62
27
357
4148
89
141
315
3968
104
330
269
3445
Monocytes [#/volume] in Blood
26484-6 [3001604]
26484-6 [3001604]
8.0e-01
1.5e+00
3.3e+00
1.0e+50
3.3e+00
2.1e+00
1.4e+00
cases:9.07%
controls:4.31%
cases:11.46%
controls:2.85%
cases:12.41%
controls:0.50%
cases:5.01%
controls:0.00%
cases:14.56%
controls:0.62%
cases:20.79%
controls:3.26%
cases:26.27%
controls:8.24%
38
180
381
3999
48
119
371
4060
52
21
367
4158
21
0
398
4179
61
26
358
4149
84
134
320
3975
98
311
275
3464
Basophils [#/volume] in Blood
26444-0 [3006315]
26444-0 [3006315]
7.8e-01
1.5e+00
3.3e+00
1.0e+50
3.3e+00
2.1e+00
1.4e+00
cases:9.07%
controls:4.36%
cases:11.46%
controls:2.85%
cases:12.41%
controls:0.50%
cases:5.01%
controls:0.00%
cases:14.56%
controls:0.62%
cases:20.79%
controls:3.24%
cases:26.27%
controls:8.29%
38
182
381
3997
48
119
371
4060
52
21
367
4158
21
0
398
4179
61
26
358
4149
84
133
320
3976
98
313
275
3462
Differential panel, method unspecified - Blood
69738-3 [42870588]
69738-3 [42870588]
8.3e-01
1.3e+00
3.3e+00
1.0e+50
3.3e+00
2.1e+00
1.3e+00
cases:6.44%
controls:2.92%
cases:7.40%
controls:2.03%
cases:8.59%
controls:0.34%
cases:3.82%
controls:0.00%
cases:9.31%
controls:0.36%
cases:13.86%
controls:2.02%
cases:16.62%
controls:4.95%
27
122
392
4057
31
85
388
4094
36
14
383
4165
16
0
403
4179
39
15
380
4160
56
83
348
4026
62
187
311
3588
Lymphocytes [#/volume] in Blood
26474-7 [3019198]
26474-7 [3019198]
7.1e-01
1.4e+00
3.3e+00
1.0e+50
3.3e+00
2.0e+00
1.4e+00
cases:9.07%
controls:4.69%
cases:11.46%
controls:2.99%
cases:12.89%
controls:0.55%
cases:5.01%
controls:0.00%
cases:14.56%
controls:0.62%
cases:20.79%
controls:3.38%
cases:26.54%
controls:8.37%
38
196
381
3983
48
125
371
4054
54
23
365
4156
21
0
398
4179
61
26
358
4149
84
139
320
3970
99
316
274
3459
Monocytes/Leukocytes in Blood
26485-3 [3019069]
26485-3 [3019069]
8.0e-01
1.4e+00
3.2e+00
1.0e+50
3.3e+00
2.0e+00
1.4e+00
cases:8.83%
controls:4.16%
cases:10.02%
controls:2.75%
cases:11.69%
controls:0.53%
cases:4.30%
controls:0.00%
cases:12.89%
controls:0.53%
cases:18.81%
controls:3.12%
cases:25.20%
controls:7.81%
37
174
382
4005
42
115
377
4064
49
22
370
4157
18
0
401
4179
54
22
365
4153
76
128
328
3981
94
295
279
3480
Eosinophils/Leukocytes in Blood
26450-7 [3006504]
26450-7 [3006504]
8.1e-01
1.4e+00
3.2e+00
1.0e+50
3.3e+00
2.0e+00
1.4e+00
cases:8.83%
controls:4.12%
cases:10.02%
controls:2.75%
cases:11.46%
controls:0.53%
cases:4.30%
controls:0.00%
cases:12.65%
controls:0.55%
cases:18.81%
controls:3.12%
cases:25.20%
controls:7.79%
37
172
382
4007
42
115
377
4064
48
22
371
4157
18
0
401
4179
53
23
366
4152
76
128
328
3981
94
294
279
3481
salmeterol and fluticasone
R03AK06 [21603280]
R03AK06 [21603280]
1.6e+00
2.0e+00
2.3e+00
—
2.1e+00
2.0e+00
1.9e+00
cases:11.46%
controls:2.63%
cases:12.17%
controls:1.79%
cases:5.01%
controls:0.50%
—
—
cases:4.53%
controls:0.55%
cases:11.63%
controls:1.80%
cases:16.35%
controls:2.86%
48
110
371
4069
51
75
368
4104
21
21
398
4158
—
19
23
400
4152
47
74
357
4035
61
108
312
3667
Basophils/Leukocytes in Blood
30180-4 [3022096]
30180-4 [3022096]
8.3e-01
1.4e+00
3.2e+00
1.0e+50
3.2e+00
2.0e+00
1.4e+00
cases:8.83%
controls:4.07%
cases:10.02%
controls:2.75%
cases:11.46%
controls:0.53%
cases:4.30%
controls:0.00%
cases:12.65%
controls:0.57%
cases:18.81%
controls:3.16%
cases:24.93%
controls:7.81%
37
170
382
4009
42
115
377
4064
48
22
371
4157
18
0
401
4179
53
24
366
4151
76
130
328
3979
93
295
280
3480
Neutrophils/Leukocytes in Blood
26511-6 [3018010]
26511-6 [3018010]
7.4e-01
1.3e+00
3.2e+00
1.0e+50
3.2e+00
2.0e+00
1.3e+00
cases:8.59%
controls:4.31%
cases:9.79%
controls:2.87%
cases:12.17%
controls:0.55%
cases:3.82%
controls:0.00%
cases:12.17%
controls:0.55%
cases:19.06%
controls:3.12%
cases:23.86%
controls:7.89%
36
180
383
3999
41
120
378
4059
51
23
368
4156
16
0
403
4179
51
23
368
4152
77
128
327
3981
89
298
284
3477
Lymphocytes/Leukocytes in Blood
26478-8 [3002030]
26478-8 [3002030]
7.2e-01
1.3e+00
3.2e+00
1.0e+50
3.2e+00
2.0e+00
1.3e+00
cases:8.59%
controls:4.36%
cases:10.02%
controls:2.87%
cases:12.17%
controls:0.55%
cases:4.30%
controls:0.00%
cases:12.89%
controls:0.60%
cases:18.81%
controls:3.16%
cases:25.20%
controls:8.21%
36
182
383
3997
42
120
377
4059
51
23
368
4156
18
0
401
4179
54
25
365
4150
76
130
328
3979
94
310
279
3465
Predominantly allergic asthma
J45.0 [45557624]
J45.0 [45557624]
2.2e+00
3.1e+00
—
1.0e+50
1.0e+50
3.3e+00
3.0e+00
cases:7.16%
controls:0.81%
cases:7.40%
controls:0.36%
—
—
cases:5.25%
controls:0.00%
cases:3.58%
controls:0.00%
cases:10.89%
controls:0.46%
cases:15.01%
controls:0.90%
30
34
389
4145
31
15
388
4164
—
22
0
397
4179
15
0
404
4175
44
19
360
4090
56
34
317
3741
Flexible bronchoscopy
UGC12 [2001303610]
UGC12 [2001303610]
2.6e+00
4.0e+00
—
1.0e+50
1.0e+50
2.7e+00
2.1e+00
cases:4.53%
controls:0.34%
cases:7.64%
controls:0.14%
—
—
cases:6.21%
controls:0.00%
cases:3.10%
controls:0.00%
cases:1.73%
controls:0.12%
cases:5.36%
controls:0.66%
19
14
400
4165
32
6
387
4173
—
26
0
393
4179
13
0
406
4175
7
5
397
4104
20
25
353
3750
C reactive protein [Mass/volume] in Serum or Plasma
1988-5 [3020460]
1988-5 [3020460]
6.7e-02
7.9e-01
2.5e+00
4.2e+00
2.2e+00
1.0e+00
5.4e-01
cases:14.80%
controls:13.97%
cases:18.38%
controls:9.31%
cases:19.09%
controls:1.89%
cases:10.26%
controls:0.17%
cases:15.99%
controls:1.99%
cases:24.26%
controls:10.51%
cases:35.66%
controls:24.45%
62
584
357
3595
77
389
342
3790
80
79
339
4100
43
7
376
4172
67
83
352
4092
98
432
306
3677
133
923
240
2852
CBC W Ordered Manual Differential panel - Blood
57782-5 [40760892]
57782-5 [40760892]
7.2e-01
1.3e+00
3.6e+00
1.0e+50
3.0e+00
1.9e+00
1.3e+00
cases:3.34%
controls:1.65%
cases:3.58%
controls:1.01%
cases:4.06%
controls:0.12%
cases:2.86%
controls:0.00%
cases:4.77%
controls:0.24%
cases:7.18%
controls:1.19%
cases:11.80%
controls:3.55%
14
69
405
4110
15
42
404
4137
17
5
402
4174
12
0
407
4179
20
10
399
4165
29
49
375
4060
44
134
329
3641
budesonide; inhalant
R03BA02 [21603285]
R03BA02 [21603285]
1.6e+00
1.9e+00
2.2e+00
—
1.5e+00
1.9e+00
1.8e+00
cases:19.57%
controls:4.50%
cases:17.18%
controls:2.90%
cases:5.25%
controls:0.62%
—
—
cases:4.30%
controls:1.01%
cases:17.08%
controls:3.02%
cases:25.47%
controls:5.35%
82
188
337
3991
72
121
347
4058
22
26
397
4153
—
18
42
401
4133
69
124
335
3985
95
202
278
3573
Office Visit
OMOP4822458 [581477]
OMOP4822458 [581477]
7.0e-01
1.1e+00
3.1e+00
—
3.2e+00
1.3e+00
1.0e+00
cases:11.22%
controls:5.91%
cases:7.16%
controls:2.39%
cases:5.49%
controls:0.26%
—
—
cases:6.92%
controls:0.29%
cases:7.67%
controls:2.24%
cases:17.96%
controls:7.15%
47
247
372
3932
30
100
389
4079
23
11
396
4168
—
29
12
390
4163
31
92
373
4017
67
270
306
3505
salbutamol; inhalant
R03AC02 [21603256]
R03AC02 [21603256]
1.2e+00
1.8e+00
2.1e+00
1.0e+50
2.2e+00
1.6e+00
1.5e+00
cases:26.49%
controls:9.69%
cases:26.25%
controls:5.65%
cases:7.64%
controls:0.98%
cases:1.91%
controls:0.00%
cases:9.31%
controls:1.10%
cases:24.26%
controls:6.01%
cases:39.68%
controls:13.22%
111
405
308
3774
110
236
309
3943
32
41
387
4138
8
0
411
4179
39
46
380
4129
98
247
306
3862
148
499
225
3276
pantoprazole; oral, parenteral
A02BC02 [21600097]
A02BC02 [21600097]
6.2e-01
8.2e-01
1.7e+00
2.5e+00
2.6e+00
1.5e+00
7.3e-01
cases:17.90%
controls:10.53%
cases:14.56%
controls:6.96%
cases:6.68%
controls:1.34%
cases:1.67%
controls:0.14%
cases:19.33%
controls:1.80%
cases:26.73%
controls:7.76%
cases:28.69%
controls:16.24%
75
440
344
3739
61
291
358
3888
28
56
391
4123
7
6
412
4173
81
75
338
4100
108
319
296
3790
107
613
266
3162
methylprednisolone; oral, parenteral
H02AB04 [21602732]
H02AB04 [21602732]
1.3e+00
2.1e+00
—
—
2.9e+00
2.3e+00
1.7e+00
cases:6.21%
controls:1.72%
cases:4.06%
controls:0.50%
—
—
—
—
cases:2.86%
controls:0.17%
cases:5.69%
controls:0.61%
cases:9.12%
controls:1.88%
26
72
393
4107
17
21
402
4158
—
—
12
7
407
4168
23
25
381
4084
34
71
339
3704
fluticasone; inhalant
R03BA05 [21603288]
R03BA05 [21603288]
1.6e+00
1.9e+00
1.6e+00
—
2.1e+00
1.4e+00
1.4e+00
cases:12.17%
controls:2.61%
cases:9.07%
controls:1.53%
cases:2.63%
controls:0.53%
—
—
cases:2.86%
controls:0.36%
cases:6.44%
controls:1.61%
cases:10.99%
controls:3.02%
51
109
368
4070
38
64
381
4115
11
22
408
4157
—
12
15
407
4160
26
66
378
4043
41
114
332
3661
fluticasone furoate
R03BA09 [45893496]
R03BA09 [45893496]
1.7e+00
1.9e+00
1.7e+00
—
2.1e+00
1.4e+00
1.3e+00
cases:12.17%
controls:2.39%
cases:8.35%
controls:1.39%
cases:2.39%
controls:0.45%
—
—
cases:2.39%
controls:0.31%
cases:5.45%
controls:1.44%
cases:9.38%
controls:2.65%
51
100
368
4079
35
58
384
4121
10
19
409
4160
—
10
13
409
4162
22
59
382
4050
35
100
338
3675
Neutrophils [#/volume] in Blood by Automated count
751-8 [3013650]
751-8 [3013650]
5.5e-01
1.2e+00
2.9e+00
—
2.8e+00
1.8e+00
1.2e+00
cases:9.07%
controls:5.46%
cases:11.69%
controls:3.69%
cases:11.93%
controls:0.74%
—
—
cases:13.37%
controls:0.93%
cases:20.54%
controls:4.02%
cases:26.01%
controls:9.54%
38
228
381
3951
49
154
370
4025
50
31
369
4148
—
56
39
363
4136
83
165
321
3944
97
360
276
3415
Abnormal findings on diagnostic imaging of lung
R91 [45548995]
R91 [45548995]
1.8e+00
4.2e+00
—
1.0e+50
1.0e+50
3.7e+00
1.0e+00
cases:3.34%
controls:0.57%
cases:11.46%
controls:0.19%
—
—
cases:4.06%
controls:0.00%
cases:4.30%
controls:0.00%
cases:6.68%
controls:0.17%
cases:2.95%
controls:1.06%
14
24
405
4155
48
8
371
4171
—
17
0
402
4179
18
0
401
4175
27
7
377
4102
11
40
362
3735
IgE [Units/volume] in Serum or Plasma
19113-0 [3005322]
19113-0 [3005322]
1.9e+00
2.7e+00
—
—
1.0e+50
3.0e+00
2.0e+00
cases:2.15%
controls:0.34%
cases:4.30%
controls:0.29%
—
—
—
—
cases:4.53%
controls:0.00%
cases:4.21%
controls:0.22%
cases:6.70%
controls:0.95%
9
14
410
4165
18
12
401
4167
—
—
19
0
400
4175
17
9
387
4100
25
36
348
3739
Chronic maxillary sinusitis
J32.0 [45586667]
J32.0 [45586667]
1.8e+00
2.3e+00
—
—
—
3.0e+00
2.4e+00
cases:3.58%
controls:0.60%
cases:2.39%
controls:0.24%
—
—
—
—
—
—
cases:3.71%
controls:0.19%
cases:6.97%
controls:0.69%
15
25
404
4154
10
10
409
4169
—
—
—
15
8
389
4101
26
26
347
3749
Erythrocyte [DistWidth] in Red Blood Cells
30385-9 [3002385]
30385-9 [3002385]
5.7e-02
5.3e-01
2.1e+00
3.6e+00
2.0e+00
7.8e-01
4.7e-01
cases:11.93%
controls:11.34%
cases:15.75%
controls:9.93%
cases:15.75%
controls:2.20%
cases:7.64%
controls:0.22%
cases:13.13%
controls:2.08%
cases:20.05%
controls:10.34%
cases:29.49%
controls:20.72%
50
474
369
3705
66
415
353
3764
66
92
353
4087
32
9
387
4170
55
87
364
4088
81
425
323
3684
110
782
263
2993
Bacterial pneumonia, unspecified
J15.9 [45557621]
J15.9 [45557621]
1.8e+00
3.8e+00
—
1.0e+50
—
2.1e+00
1.7e+00
cases:3.82%
controls:0.65%
cases:6.21%
controls:0.14%
—
—
cases:1.43%
controls:0.00%
—
—
cases:2.23%
controls:0.27%
cases:5.09%
controls:0.98%
16
27
403
4152
26
6
393
4173
—
6
0
413
4179
—
9
11
395
4098
19
37
354
3738
Medical doctor
Z2221 [2001311556]
Z2221 [2001311556]
6.6e-01
1.6e+00
2.3e+00
1.0e+50
2.4e+00
1.5e+00
1.5e+00
cases:6.44%
controls:3.45%
cases:5.25%
controls:1.10%
cases:2.63%
controls:0.26%
cases:2.15%
controls:0.00%
cases:1.91%
controls:0.17%
cases:5.20%
controls:1.22%
cases:12.33%
controls:3.05%
27
144
392
4035
22
46
397
4133
11
11
408
4168
9
0
410
4179
8
7
411
4168
21
50
383
4059
46
115
327
3660
doxycycline; oral, parenteral
J01AA02 [21602800]
J01AA02 [21602800]
7.9e-01
1.6e+00
3.2e+00
—
2.0e+00
8.6e-01
7.8e-01
cases:32.22%
controls:17.78%
cases:21.96%
controls:5.29%
cases:10.74%
controls:0.50%
—
—
cases:3.34%
controls:0.46%
cases:12.38%
controls:5.65%
cases:30.83%
controls:16.93%
135
743
284
3436
92
221
327
3958
45
21
374
4158
—
14
19
405
4156
50
232
354
3877
115
639
258
3136
Erythrocyte sedimentation rate [Velocity] in Red Blood Cells by Westergren method
4537-7 [3013707]
4537-7 [3013707]
2.8e-01
1.1e+00
2.9e+00
—
2.9e+00
1.5e+00
8.5e-01
cases:10.98%
controls:8.52%
cases:11.93%
controls:4.50%
cases:11.46%
controls:0.69%
—
—
cases:10.74%
controls:0.67%
cases:20.05%
controls:5.28%
cases:28.15%
controls:14.30%
46
356
373
3823
50
188
369
3991
48
29
371
4150
—
45
28
374
4147
81
217
323
3892
105
540
268
3235
formoterol and beclometasone
R03AK08 [43534839]
R03AK08 [43534839]
1.9e+00
2.4e+00
—
—
—
2.7e+00
2.2e+00
cases:2.15%
controls:0.34%
cases:3.10%
controls:0.29%
—
—
—
—
—
—
cases:4.21%
controls:0.29%
cases:6.43%
controls:0.74%
9
14
410
4165
13
12
406
4167
—
—
—
17
12
387
4097
24
28
349
3747
roxithromycin; oral
J01FA06 [21602974]
J01FA06 [21602974]
9.7e-01
2.5e+00
—
—
2.6e+00
2.0e+00
1.2e+00
cases:11.69%
controls:4.76%
cases:9.31%
controls:0.84%
—
—
—
—
cases:2.15%
controls:0.17%
cases:6.93%
controls:1.02%
cases:12.87%
controls:4.32%
49
199
370
3980
39
35
380
4144
—
—
9
7
410
4168
28
42
376
4067
48
163
325
3612
Supplier / Service Provider
OMOP5117446 [33004]
OMOP5117446 [33004]
-8.4e-01
1.1e-01
1.3e+00
—
—
4.3e+00
4.3e+00
cases:13.60%
controls:26.66%
cases:9.07%
controls:8.23%
cases:3.34%
controls:0.93%
—
—
—
—
cases:13.86%
controls:0.22%
cases:26.81%
controls:0.48%
57
1114
362
3065
38
344
381
3835
14
39
405
4140
—
—
56
9
348
4100
100
18
273
3757
Clinical & Laboratory Dermatological Immunology Physician
207NI0002X [38003841]
207NI0002X [38003841]
8.0e-01
1.0e+00
2.4e+00
—
2.4e+00
1.4e+00
1.0e+00
cases:11.93%
controls:5.74%
cases:6.21%
controls:2.30%
cases:4.06%
controls:0.38%
—
—
cases:2.86%
controls:0.26%
cases:8.42%
controls:2.19%
cases:16.62%
controls:6.60%
50
240
369
3939
26
96
393
4083
17
16
402
4163
—
12
11
407
4164
34
90
370
4019
62
249
311
3526
terbutaline; inhalant
R03AC03 [21603257]
R03AC03 [21603257]
1.1e+00
2.1e+00
—
—
2.5e+00
1.7e+00
1.6e+00
cases:6.92%
controls:2.32%
cases:6.92%
controls:0.89%
—
—
—
—
cases:1.67%
controls:0.14%
cases:4.21%
controls:0.83%
cases:8.31%
controls:1.83%
29
97
390
4082
29
37
390
4142
—
—
7
6
412
4169
17
34
387
4075
31
69
342
3706
formoterol; inhalant
R03AC13 [21603267]
R03AC13 [21603267]
2.1e+00
2.5e+00
—
—
—
2.4e+00
2.1e+00
cases:4.53%
controls:0.60%
cases:4.06%
controls:0.36%
—
—
—
—
—
—
cases:3.96%
controls:0.39%
cases:4.02%
controls:0.53%
19
25
400
4154
17
15
402
4164
—
—
—
16
16
388
4093
15
20
358
3755
Polyp of nasal cavity
J33.0 [45562447]
J33.0 [45562447]
2.8e+00
3.0e+00
—
—
1.0e+50
—
3.1e+00
cases:3.34%
controls:0.22%
cases:3.34%
controls:0.17%
—
—
—
—
cases:1.43%
controls:0.00%
—
—
cases:5.09%
controls:0.24%
14
9
405
4170
14
7
405
4172
—
—
6
0
413
4175
—
19
9
354
3766
Chronic asthma and similar chronic obstructive pulmonary diseases
203 [2001600201]
203 [2001600201]
1.5e+00
2.1e+00
—
—
—
3.0e+00
2.3e+00
cases:6.92%
controls:1.65%
cases:3.34%
controls:0.41%
—
—
—
—
—
—
cases:5.69%
controls:0.29%
cases:9.92%
controls:1.14%
29
69
390
4110
14
17
405
4162
—
—
—
23
12
381
4097
37
43
336
3732
Short blood count panel - Blood
55429-5 [40758558]
55429-5 [40758558]
2.6e-01
1.2e+00
2.6e+00
—
2.3e+00
1.5e+00
1.1e+00
cases:3.10%
controls:2.42%
cases:4.30%
controls:1.29%
cases:3.58%
controls:0.26%
—
—
cases:3.58%
controls:0.36%
cases:6.93%
controls:1.56%
cases:11.80%
controls:4.13%
13
101
406
4078
18
54
401
4125
15
11
404
4168
—
15
15
404
4160
28
64
376
4045
44
156
329
3619
Normoblasts [#/volume] in Blood
715-3 [3021589]
715-3 [3021589]
3.2e-01
9.5e-01
2.5e+00
—
2.6e+00
1.6e+00
1.2e+00
cases:5.25%
controls:3.88%
cases:7.64%
controls:3.09%
cases:8.11%
controls:0.74%
—
—
cases:9.79%
controls:0.84%
cases:14.60%
controls:3.21%
cases:20.91%
controls:7.31%
22
162
397
4017
32
129
387
4050
34
31
385
4148
—
41
35
378
4140
59
132
345
3977
78
276
295
3499
Internal Medicine
11 [38004456]
11 [38004456]
5.8e-01
1.4e+00
2.8e+00
1.0e+50
1.8e+00
1.4e+00
8.4e-01
cases:31.50%
controls:20.51%
cases:28.16%
controls:8.54%
cases:21.48%
controls:1.70%
cases:20.05%
controls:0.00%
cases:8.11%
controls:1.49%
cases:28.47%
controls:8.88%
cases:39.41%
controls:21.91%
132
857
287
3322
118
357
301
3822
90
71
329
4108
84
0
335
4179
34
62
385
4113
115
365
289
3744
147
827
226
2948
levofloxacin; inhalant, oral, parenteral
J01MA12 [21603019]
J01MA12 [21603019]
1.2e+00
2.1e+00
—
—
2.5e+00
1.6e+00
1.2e+00
cases:5.73%
controls:1.75%
cases:4.53%
controls:0.55%
—
—
—
—
cases:1.43%
controls:0.12%
cases:2.48%
controls:0.54%
cases:7.51%
controls:2.41%
24
73
395
4106
19
23
400
4156
—
—
6
5
413
4170
10
22
394
4087
28
91
345
3684
mometasone; nasal
R01AD09 [21605051]
R01AD09 [21605051]
1.0e+00
1.4e+00
1.6e+00
—
1.9e+00
1.4e+00
1.2e+00
cases:17.42%
controls:6.94%
cases:12.17%
controls:3.18%
cases:2.63%
controls:0.53%
—
—
cases:1.91%
controls:0.29%
cases:11.39%
controls:3.09%
cases:21.18%
controls:7.76%
73
290
346
3889
51
133
368
4046
11
22
408
4157
—
8
12
411
4163
46
127
358
3982
79
293
294
3482
Spirometry for bronchospasm with prolonged evaluation after bronchodilator
113016006 [4010399]
113016006 [4010399]
1.4e+00
2.0e+00
—
—
—
3.0e+00
2.1e+00
cases:3.34%
controls:0.89%
cases:3.34%
controls:0.45%
—
—
—
—
—
—
cases:6.19%
controls:0.34%
cases:9.12%
controls:1.17%
14
37
405
4142
14
19
405
4160
—
—
—
25
14
379
4095
34
44
339
3731
Emergency Room Visit
ER [9203]
ER [9203]
5.0e-01
1.4e+00
3.0e+00
—
1.6e+00
1.2e+00
7.4e-01
cases:37.23%
controls:26.51%
cases:30.55%
controls:9.69%
cases:21.96%
controls:1.41%
—
—
cases:5.73%
controls:1.17%
cases:27.23%
controls:10.10%
cases:46.65%
controls:29.51%
156
1108
263
3071
128
405
291
3774
92
59
327
4120
—
24
49
395
4126
110
415
294
3694
174
1114
199
2661
Pneumonia, unspecified
J18.9 [45601123]
J18.9 [45601123]
1.3e+00
3.2e+00
—
—
—
2.4e+00
1.3e+00
cases:7.64%
controls:2.23%
cases:15.99%
controls:0.77%
—
—
—
—
—
—
cases:9.90%
controls:1.00%
cases:14.21%
controls:4.21%
32
93
387
4086
67
32
352
4147
—
—
—
40
41
364
4068
53
159
320
3616
MCH [Entitic mass]
28539-5 [3035941]
28539-5 [3035941]
-1.7e-02
3.3e-01
1.9e+00
3.8e+00
1.7e+00
4.6e-01
1.8e-01
cases:18.38%
controls:18.64%
cases:21.48%
controls:16.42%
cases:20.53%
controls:3.78%
cases:10.74%
controls:0.26%
cases:17.42%
controls:3.57%
cases:25.50%
controls:17.72%
cases:37.27%
controls:33.25%
77
779
342
3400
90
686
329
3493
86
158
333
4021
45
11
374
4168
73
149
346
4026
103
728
301
3381
139
1255
234
2520
Erythrocytes [#/volume] in Blood
26453-1 [3026361]
26453-1 [3026361]
-1.9e-02
3.3e-01
1.9e+00
3.8e+00
1.7e+00
4.6e-01
1.7e-01
cases:18.38%
controls:18.66%
cases:21.48%
controls:16.39%
cases:20.53%
controls:3.78%
cases:10.74%
controls:0.26%
cases:17.42%
controls:3.59%
cases:25.50%
controls:17.77%
cases:37.27%
controls:33.30%
77
780
342
3399
90
685
329
3494
86
158
333
4021
45
11
374
4168
73
150
346
4025
103
730
301
3379
139
1257
234
2518
MCV [Entitic mean volume] in Red Blood Cells
30428-7 [3024731]
30428-7 [3024731]
-1.9e-02
3.2e-01
1.9e+00
3.8e+00
1.7e+00
4.6e-01
1.7e-01
cases:18.38%
controls:18.66%
cases:21.24%
controls:16.42%
cases:20.53%
controls:3.80%
cases:10.74%
controls:0.26%
cases:17.42%
controls:3.59%
cases:25.50%
controls:17.69%
cases:37.27%
controls:33.30%
77
780
342
3399
89
686
330
3493
86
159
333
4020
45
11
374
4168
73
150
346
4025
103
727
301
3382
139
1257
234
2518
Platelets [#/volume] in Blood
26515-7 [3007461]
26515-7 [3007461]
-1.4e-02
3.4e-01
1.9e+00
3.8e+00
1.7e+00
4.6e-01
1.8e-01
cases:18.38%
controls:18.59%
cases:21.48%
controls:16.34%
cases:20.53%
controls:3.80%
cases:10.74%
controls:0.26%
cases:17.42%
controls:3.59%
cases:25.50%
controls:17.69%
cases:37.27%
controls:33.19%
77
777
342
3402
90
683
329
3496
86
159
333
4020
45
11
374
4168
73
150
346
4025
103
727
301
3382
139
1253
234
2522
Leukocytes [#/volume] in Blood
26464-8 [3010813]
26464-8 [3010813]
-2.1e-02
3.3e-01
1.9e+00
3.8e+00
1.7e+00
4.6e-01
1.8e-01
cases:18.38%
controls:18.69%
cases:21.48%
controls:16.42%
cases:20.53%
controls:3.80%
cases:10.74%
controls:0.26%
cases:17.42%
controls:3.57%
cases:25.50%
controls:17.81%
cases:37.27%
controls:33.25%
77
781
342
3398
90
686
329
3493
86
159
333
4020
45
11
374
4168
73
149
346
4026
103
732
301
3377
139
1255
234
2520
Hemoglobin [Mass/volume] in Blood
718-7 [3000963]
718-7 [3000963]
-6.4e-03
3.2e-01
1.9e+00
3.8e+00
1.7e+00
4.6e-01
1.8e-01
cases:18.62%
controls:18.71%
cases:21.48%
controls:16.51%
cases:20.53%
controls:3.80%
cases:10.74%
controls:0.26%
cases:17.42%
controls:3.59%
cases:25.50%
controls:17.77%
cases:37.53%
controls:33.38%
78
782
341
3397
90
690
329
3489
86
159
333
4020
45
11
374
4168
73
150
346
4025
103
730
301
3379
140
1260
233
2515
pH of Serum or Plasma
2753-2 [3018418]
2753-2 [3018418]
1.7e-01
9.7e-01
2.8e+00
—
2.7e+00
1.4e+00
4.6e-01
cases:3.34%
controls:2.82%
cases:5.01%
controls:1.96%
cases:3.58%
controls:0.22%
—
—
cases:3.10%
controls:0.22%
cases:6.19%
controls:1.68%
cases:7.77%
controls:5.06%
14
118
405
4061
21
82
398
4097
15
9
404
4170
—
13
9
406
4166
25
69
379
4040
29
191
344
3584
Hematocrit [Volume Fraction] of Blood by calculation
20570-8 [3009542]
20570-8 [3009542]
-1.7e-02
3.3e-01
1.9e+00
3.7e+00
1.7e+00
4.6e-01
1.7e-01
cases:18.38%
controls:18.64%
cases:21.48%
controls:16.42%
cases:20.53%
controls:3.80%
cases:10.74%
controls:0.29%
cases:17.42%
controls:3.57%
cases:25.50%
controls:17.72%
cases:37.27%
controls:33.30%
77
779
342
3400
90
686
329
3493
86
159
333
4020
45
12
374
4167
73
149
346
4026
103
728
301
3381
139
1257
234
2518
Epithelial cells [#/volume] in Urine
30383-4 [3000850]
30383-4 [3000850]
-2.1e-01
1.3e+00
2.5e+00
—
2.6e+00
1.5e+00
6.9e-01
cases:1.91%
controls:2.35%
cases:3.10%
controls:0.86%
cases:1.67%
controls:0.14%
—
—
cases:2.15%
controls:0.17%
cases:3.47%
controls:0.83%
cases:6.17%
controls:3.18%
8
98
411
4081
13
36
406
4143
7
6
412
4173
—
9
7
410
4168
14
34
390
4075
23
120
350
3655
fluticasone; nasal
R01AD08 [21605050]
R01AD08 [21605050]
1.2e+00
1.6e+00
2.0e+00
—
1.3e+00
1.6e+00
1.4e+00
cases:17.90%
controls:6.34%
cases:14.32%
controls:3.13%
cases:2.86%
controls:0.41%
—
—
cases:1.91%
controls:0.55%
cases:12.62%
controls:2.87%
cases:23.06%
controls:7.02%
75
265
344
3914
60
131
359
4048
12
17
407
4162
—
8
23
411
4152
51
118
353
3991
86
265
287
3510
fluticasone furoate; nasal
R01AD12 [21605053]
R01AD12 [21605053]
1.2e+00
1.6e+00
2.0e+00
—
1.3e+00
1.6e+00
1.4e+00
cases:17.90%
controls:6.34%
cases:14.32%
controls:3.13%
cases:2.86%
controls:0.41%
—
—
cases:1.91%
controls:0.55%
cases:12.62%
controls:2.87%
cases:23.06%
controls:7.02%
75
265
344
3914
60
131
359
4048
12
17
407
4162
—
8
23
411
4152
51
118
353
3991
86
265
287
3510
Sodium [Moles/volume] in Serum or Plasma
2951-2 [3019550]
2951-2 [3019550]
-8.9e-02
3.1e-01
1.8e+00
3.6e+00
1.9e+00
4.4e-01
2.3e-01
cases:15.27%
controls:16.46%
cases:17.66%
controls:13.64%
cases:14.56%
controls:2.85%
cases:8.83%
controls:0.26%
cases:15.04%
controls:2.51%
cases:21.53%
controls:14.97%
cases:34.05%
controls:29.11%
64
688
355
3491
74
570
345
3609
61
119
358
4060
37
11
382
4168
63
105
356
4070
87
615
317
3494
127
1099
246
2676
Potassium [Moles/volume] in Serum or Plasma
2823-3 [3023103]
2823-3 [3023103]
-1.0e-01
3.2e-01
1.8e+00
3.6e+00
1.9e+00
4.5e-01
2.2e-01
cases:15.27%
controls:16.68%
cases:18.14%
controls:13.85%
cases:14.56%
controls:2.87%
cases:8.83%
controls:0.26%
cases:15.51%
controls:2.71%
cases:21.78%
controls:15.14%
cases:34.05%
controls:29.27%
64
697
355
3482
76
579
343
3600
61
120
358
4059
37
11
382
4168
65
113
354
4062
88
622
316
3487
127
1105
246
2670
Otolaryngology
4 [38004449]
4 [38004449]
8.5e-01
1.3e+00
1.3e+00
—
1.9e+00
1.4e+00
9.8e-01
cases:18.85%
controls:9.05%
cases:12.89%
controls:4.00%
cases:2.63%
controls:0.72%
—
—
cases:3.58%
controls:0.55%
cases:14.11%
controls:4.04%
cases:24.66%
controls:10.91%
79
378
340
3801
54
167
365
4012
11
30
408
4149
—
15
23
404
4152
57
166
347
3943
92
412
281
3363
ciclesonide; inhalant
R03BA08 [21603291]
R03BA08 [21603291]
1.7e+00
2.3e+00
—
—
—
1.9e+00
1.7e+00
cases:2.86%
controls:0.53%
cases:3.10%
controls:0.34%
—
—
—
—
—
—
cases:3.22%
controls:0.51%
cases:7.24%
controls:1.38%
12
22
407
4157
13
14
406
4165
—
—
—
13
21
391
4088
27
52
346
3723
ciclesonide; nasal
R01AD13 [43534836]
R01AD13 [43534836]
1.7e+00
2.3e+00
—
—
—
1.9e+00
1.7e+00
cases:2.86%
controls:0.53%
cases:3.10%
controls:0.34%
—
—
—
—
—
—
cases:3.22%
controls:0.51%
cases:7.24%
controls:1.38%
12
22
407
4157
13
14
406
4165
—
—
—
13
21
391
4088
27
52
346
3723
omeprazole; oral, parenteral
A02BC01 [21600096]
A02BC01 [21600096]
6.8e-01
1.2e+00
2.2e+00
—
2.2e+00
1.3e+00
7.0e-01
cases:6.44%
controls:3.37%
cases:5.01%
controls:1.60%
cases:2.63%
controls:0.31%
—
—
cases:4.30%
controls:0.50%
cases:6.68%
controls:1.92%
cases:8.31%
controls:4.32%
27
141
392
4038
21
67
398
4112
11
13
408
4166
—
18
21
401
4154
27
79
377
4030
31
163
342
3612
Outpatient Hospital
22 [8756]
22 [8756]
3.8e-01
1.2e+00
2.4e+00
—
2.3e+00
8.6e-01
6.8e-01
cases:28.40%
controls:21.37%
cases:19.81%
controls:6.92%
cases:8.59%
controls:0.84%
—
—
cases:6.21%
controls:0.65%
cases:16.58%
controls:7.76%
cases:34.58%
controls:21.06%
119
893
300
3286
83
289
336
3890
36
35
383
4144
—
26
27
393
4148
67
319
337
3790
129
795
244
2980
Bilirubin.total [Moles/volume] in Serum or Plasma
14631-6 [3006140]
14631-6 [3006140]
1.2e-01
1.1e+00
2.1e+00
—
2.4e+00
1.2e+00
6.8e-01
cases:5.73%
controls:5.10%
cases:7.88%
controls:2.70%
cases:4.30%
controls:0.53%
—
—
cases:5.97%
controls:0.60%
cases:9.41%
controls:3.12%
cases:16.89%
controls:9.35%
24
213
395
3966
33
113
386
4066
18
22
401
4157
—
25
25
394
4150
38
128
366
3981
63
353
310
3422
Proteinase 3 Ab [Units/volume] in Serum
6968-2 [3009445]
6968-2 [3009445]
1.7e+00
2.9e+00
1.0e+50
1.0e+50
1.0e+50
—
2.9e+00
cases:1.91%
controls:0.36%
cases:4.06%
controls:0.24%
cases:3.58%
controls:0.00%
cases:1.67%
controls:0.00%
cases:6.68%
controls:0.00%
—
—
cases:5.90%
controls:0.34%
8
15
411
4164
17
10
402
4169
15
0
404
4179
7
0
412
4179
28
0
391
4175
—
22
13
351
3762
prednisone
A07EA03 [21600655]
A07EA03 [21600655]
1.5e+00
2.2e+00
—
—
—
2.3e+00
1.4e+00
cases:6.68%
controls:1.51%
cases:4.30%
controls:0.48%
—
—
—
—
—
—
cases:4.46%
controls:0.49%
cases:5.09%
controls:1.35%
28
63
391
4116
18
20
401
4159
—
—
—
18
20
386
4089
19
51
354
3724
prednisone; oral
H02AB07 [21602735]
H02AB07 [21602735]
1.5e+00
2.2e+00
—
—
—
2.3e+00
1.4e+00
cases:6.68%
controls:1.51%
cases:4.30%
controls:0.48%
—
—
—
—
—
—
cases:4.46%
controls:0.49%
cases:5.09%
controls:1.35%
28
63
391
4116
18
20
401
4159
—
—
—
18
20
386
4089
19
51
354
3724
MCHC [Entitic Mass/volume] in Red Blood Cells
28540-3 [3003338]
28540-3 [3003338]
1.3e-02
4.4e-01
1.9e+00
3.8e+00
1.7e+00
4.4e-01
4.8e-02
cases:13.84%
controls:13.69%
cases:16.95%
controls:11.58%
cases:15.04%
controls:2.49%
cases:6.92%
controls:0.17%
cases:11.93%
controls:2.51%
cases:18.56%
controls:12.78%
cases:26.27%
controls:25.35%
58
572
361
3607
71
484
348
3695
63
104
356
4075
29
7
390
4172
50
105
369
4070
75
525
329
3584
98
957
275
2818
Calcium.ionized [Moles/volume] in Serum or Plasma
1995-0 [3021347]
1995-0 [3021347]
4.2e-02
1.0e+00
2.6e+00
1.0e+50
2.5e+00
1.1e+00
3.4e-01
cases:4.53%
controls:4.36%
cases:7.40%
controls:2.75%
cases:4.77%
controls:0.36%
cases:1.67%
controls:0.00%
cases:4.30%
controls:0.36%
cases:7.92%
controls:2.65%
cases:10.72%
controls:7.84%
19
182
400
3997
31
115
388
4064
20
15
399
4164
7
0
412
4179
18
15
401
4160
32
109
372
4000
40
296
333
3479
Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI)/1.73 sq M
62238-1 [40764999]
62238-1 [40764999]
7.2e-02
2.9e-01
1.6e+00
3.6e+00
1.6e+00
5.3e-01
2.8e-01
cases:12.41%
controls:11.65%
cases:12.89%
controls:10.00%
cases:10.02%
controls:2.30%
cases:5.97%
controls:0.17%
cases:9.55%
controls:2.06%
cases:16.83%
controls:10.64%
cases:26.54%
controls:21.40%
52
487
367
3692
54
418
365
3761
42
96
377
4083
25
7
394
4172
40
86
379
4089
68
437
336
3672
99
808
274
2967
vilanterol and fluticasone furoate
R03AK10 [43534841]
R03AK10 [43534841]
2.0e+00
—
—
—
—
3.3e+00
2.0e+00
cases:1.67%
controls:0.24%
—
—
—
—
—
—
—
—
cases:3.22%
controls:0.12%
cases:4.29%
controls:0.58%
7
10
412
4169
—
—
—
—
13
5
391
4104
16
22
357
3753
amoxicillin and beta-lactamase inhibitor; oral, parenteral
J01CR02 [21602863]
J01CR02 [21602863]
8.0e-01
2.0e+00
2.2e+00
—
—
1.2e+00
9.6e-01
cases:12.41%
controls:6.01%
cases:10.50%
controls:1.51%
cases:2.63%
controls:0.31%
—
—
—
—
cases:6.44%
controls:1.97%
cases:17.43%
controls:7.50%
52
251
367
3928
44
63
375
4116
11
13
408
4166
—
—
26
81
378
4028
65
283
308
3492
calcium (different salts in combination); oral
A12AA20 [21600872]
A12AA20 [21600872]
6.9e-01
9.3e-01
7.9e-01
—
2.1e+00
1.9e+00
1.5e+00
cases:12.17%
controls:6.51%
cases:12.65%
controls:5.41%
cases:2.86%
controls:1.32%
—
—
cases:9.31%
controls:1.27%
cases:27.72%
controls:5.50%
cases:34.05%
controls:9.88%
51
272
368
3907
53
226
366
3953
12
55
407
4124
—
39
53
380
4122
112
226
292
3883
127
373
246
3402
alendronic acid; oral
M05BA04 [21604152]
M05BA04 [21604152]
2.2e-01
1.3e+00
—
—
2.7e+00
2.1e+00
2.2e+00
cases:1.67%
controls:1.34%
cases:2.15%
controls:0.62%
—
—
—
—
cases:2.86%
controls:0.19%
cases:5.94%
controls:0.73%
cases:12.06%
controls:1.43%
7
56
412
4123
9
26
410
4153
—
—
12
8
407
4167
24
30
380
4079
45
54
328
3721
Pharmacy visit
OMOP4822462 [581458]
OMOP4822462 [581458]
3.0e-01
9.6e-01
1.4e+00
2.0e+00
1.7e+00
1.1e+00
9.5e-01
cases:89.26%
controls:86.00%
cases:90.45%
controls:78.34%
cases:73.75%
controls:41.61%
cases:14.80%
controls:2.37%
cases:79.71%
controls:42.32%
cases:92.33%
controls:79.53%
cases:96.78%
controls:92.11%
374
3594
45
585
379
3274
40
905
309
1739
110
2440
62
99
357
4080
334
1767
85
2408
373
3268
31
841
361
3477
12
298
INR in Blood by Coagulation assay
34714-6 [3032080]
34714-6 [3032080]
8.0e-02
8.8e-01
1.3e+00
2.8e+00
1.4e+00
7.6e-01
2.5e-01
cases:5.73%
controls:5.31%
cases:7.16%
controls:3.11%
cases:3.58%
controls:1.03%
cases:1.91%
controls:0.12%
cases:3.82%
controls:1.01%
cases:7.18%
controls:3.48%
cases:10.72%
controls:8.56%
24
222
395
3957
30
130
389
4049
15
43
404
4136
8
5
411
4174
16
42
403
4133
29
143
375
3966
40
323
333
3452
Asthma
J45 [45596282]
J45 [45596282]
1.5e+00
2.1e+00
—
—
—
1.9e+00
1.6e+00
cases:7.40%
controls:1.75%
cases:4.53%
controls:0.57%
—
—
—
—
—
—
cases:3.96%
controls:0.63%
cases:8.85%
controls:2.01%
31
73
388
4106
19
24
400
4155
—
—
—
16
26
388
4083
33
76
340
3699
Leukocytes [#/volume] in Urine
30405-5 [3018095]
30405-5 [3018095]
-2.3e-02
9.9e-01
2.0e+00
—
2.8e+00
1.2e+00
3.9e-01
cases:3.58%
controls:3.66%
cases:5.01%
controls:1.91%
cases:2.39%
controls:0.34%
—
—
cases:4.30%
controls:0.26%
cases:5.94%
controls:1.92%
cases:9.38%
controls:6.54%
15
153
404
4026
21
80
398
4099
10
14
409
4165
—
18
11
401
4164
24
79
380
4030
35
247
338
3528
Creatinine [Moles/volume] in Serum or Plasma
14682-9 [3020564]
14682-9 [3020564]
-7.0e-02
2.7e-01
1.6e+00
3.5e+00
1.7e+00
3.5e-01
1.9e-01
cases:16.71%
controls:17.71%
cases:19.09%
controls:15.24%
cases:15.99%
controls:3.57%
cases:9.07%
controls:0.29%
cases:15.27%
controls:3.31%
cases:22.52%
controls:17.01%
cases:35.39%
controls:31.26%
70
740
349
3439
80
637
339
3542
67
149
352
4030
38
12
381
4167
64
138
355
4037
91
699
313
3410
132
1180
241
2595
theophylline; oral, parenteral, rectal
R03DA04 [21603332]
R03DA04 [21603332]
1.8e+00
1.9e+00
—
—
—
1.4e+00
1.8e+00
cases:4.53%
controls:0.81%
cases:3.58%
controls:0.57%
—
—
—
—
—
—
cases:2.72%
controls:0.66%
cases:5.09%
controls:0.90%
19
34
400
4145
15
24
404
4155
—
—
—
11
27
393
4082
19
34
354
3741
Mixed asthma
J45.8 [45548118]
J45.8 [45548118]
2.4e+00
2.3e+00
—
1.0e+50
—
2.3e+00
2.0e+00
cases:2.15%
controls:0.19%
cases:1.19%
controls:0.12%
—
—
cases:1.19%
controls:0.00%
—
—
cases:1.73%
controls:0.17%
cases:2.14%
controls:0.29%
9
8
410
4171
5
5
414
4174
—
5
0
414
4179
—
7
7
397
4102
8
11
365
3764
Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma
6768-6 [3035995]
6768-6 [3035995]
1.2e-01
7.9e-01
2.2e+00
—
2.2e+00
1.0e+00
5.8e-01
cases:10.26%
controls:9.24%
cases:11.93%
controls:5.77%
cases:8.59%
controls:1.03%
—
—
cases:9.79%
controls:1.20%
cases:15.59%
controls:6.33%
cases:25.74%
controls:16.26%
43
386
376
3793
50
241
369
3938
36
43
383
4136
—
41
50
378
4125
63
260
341
3849
96
614
277
3161
Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Serum or Plasma
19072-8 [3016431]
19072-8 [3016431]
5.6e-02
8.7e-01
2.5e+00
—
2.3e+00
1.0e+00
2.9e-01
cases:5.25%
controls:4.98%
cases:6.92%
controls:3.02%
cases:4.53%
controls:0.38%
—
—
cases:4.06%
controls:0.41%
cases:8.42%
controls:3.16%
cases:12.06%
controls:9.30%
22
208
397
3971
29
126
390
4053
19
16
400
4163
—
17
17
402
4158
34
130
370
3979
45
351
328
3424
Glucose [Moles/volume] in Serum or Plasma
14749-6 [3013826]
14749-6 [3013826]
-2.7e-01
1.1e+00
2.5e+00
1.0e+50
2.2e+00
9.7e-01
4.5e-01
cases:4.77%
controls:6.15%
cases:8.83%
controls:3.21%
cases:4.77%
controls:0.41%
cases:2.39%
controls:0.00%
cases:3.82%
controls:0.46%
cases:8.42%
controls:3.36%
cases:16.62%
controls:11.26%
20
257
399
3922
37
134
382
4045
20
17
399
4162
10
0
409
4179
16
19
403
4156
34
138
370
3971
62
425
311
3350
Erythrocytes [#/volume] in Urine
30391-7 [3002582]
30391-7 [3002582]
-2.4e-01
1.0e+00
1.8e+00
—
2.6e+00
1.2e+00
4.4e-01
cases:2.63%
controls:3.30%
cases:4.53%
controls:1.72%
cases:1.91%
controls:0.31%
—
—
cases:3.58%
controls:0.26%
cases:5.45%
controls:1.65%
cases:8.58%
controls:5.70%
11
138
408
4041
19
72
400
4107
8
13
411
4166
—
15
11
404
4164
22
68
382
4041
32
215
341
3560
Prothrombin time (PT) actual/Normal
5894-1 [3033658]
5894-1 [3033658]
-5.5e-01
1.0e+00
2.8e+00
—
2.7e+00
1.0e+00
5.3e-01
cases:1.67%
controls:2.85%
cases:3.82%
controls:1.41%
cases:2.39%
controls:0.14%
—
—
cases:2.39%
controls:0.17%
cases:3.22%
controls:1.19%
cases:6.43%
controls:3.89%
7
119
412
4060
16
59
403
4120
10
6
409
4173
—
10
7
409
4168
13
49
391
4060
24
147
349
3628
Troponin T.cardiac [Mass/volume] in Serum or Plasma
6598-7 [3019800]
6598-7 [3019800]
5.1e-01
1.1e+00
2.6e+00
1.0e+50
2.0e+00
8.9e-01
5.3e-01
cases:5.73%
controls:3.52%
cases:5.01%
controls:1.79%
cases:3.10%
controls:0.24%
cases:1.67%
controls:0.00%
cases:2.39%
controls:0.34%
cases:4.70%
controls:2.00%
cases:10.99%
controls:6.81%
24
147
395
4032
21
75
398
4104
13
10
406
4169
7
0
412
4179
10
14
409
4161
19
82
385
4027
41
257
332
3518
Thorax CT examination
GD1AD [2001303618]
GD1AD [2001303618]
—
2.0e+00
1.0e+50
1.0e+50
—
2.5e+00
2.0e+00
—
—
cases:1.43%
controls:0.19%
cases:1.67%
controls:0.00%
cases:1.43%
controls:0.00%
—
—
cases:2.23%
controls:0.19%
cases:3.49%
controls:0.50%
—
6
8
413
4171
7
0
412
4179
6
0
413
4179
—
9
8
395
4101
13
19
360
3756
CBC panel - Blood by Automated count
58410-2 [40761511]
58410-2 [40761511]
-2.8e-02
2.9e-01
1.6e+00
3.2e+00
1.6e+00
3.3e-01
2.2e-01
cases:15.75%
controls:16.13%
cases:15.51%
controls:12.08%
cases:11.22%
controls:2.46%
cases:4.06%
controls:0.17%
cases:9.55%
controls:2.13%
cases:16.09%
controls:12.12%
cases:30.83%
controls:26.33%
66
674
353
3505
65
505
354
3674
47
103
372
4076
17
7
402
4172
40
89
379
4086
65
498
339
3611
115
994
258
2781
tiotropium bromide; inhalant
R03BB04 [21603296]
R03BB04 [21603296]
1.3e+00
1.6e+00
1.4e+00
—
9.6e-01
1.7e+00
1.7e+00
cases:5.49%
controls:1.56%
cases:5.25%
controls:1.12%
cases:1.19%
controls:0.29%
—
—
cases:1.43%
controls:0.55%
cases:6.68%
controls:1.34%
cases:9.65%
controls:1.91%
23
65
396
4114
22
47
397
4132
5
12
414
4167
—
6
23
413
4152
27
55
377
4054
36
72
337
3703
moxifloxacin; oral, parenteral
J01MA14 [21603021]
J01MA14 [21603021]
2.3e+00
—
—
—
—
2.2e+00
1.8e+00
cases:5.01%
controls:0.55%
—
—
—
—
—
—
—
—
cases:1.98%
controls:0.22%
cases:4.83%
controls:0.85%
21
23
398
4156
—
—
—
—
8
9
396
4100
18
32
355
3743
IgG [Mass/volume] in Serum or Plasma
2465-3 [3005719]
2465-3 [3005719]
1.1e+00
1.9e+00
—
—
—
2.7e+00
1.6e+00
cases:2.15%
controls:0.74%
cases:2.15%
controls:0.34%
—
—
—
—
—
—
cases:3.71%
controls:0.27%
cases:5.09%
controls:1.03%
9
31
410
4148
9
14
410
4165
—
—
—
15
11
389
4098
19
39
354
3736
Laboratory Visit
OMOP4822461 [32036]
OMOP4822461 [32036]
-8.5e-02
1.4e-01
1.5e+00
3.4e+00
1.4e+00
2.5e-01
1.2e-01
cases:19.33%
controls:20.70%
cases:22.91%
controls:20.51%
cases:22.91%
controls:6.48%
cases:13.13%
controls:0.53%
cases:20.29%
controls:6.18%
cases:26.98%
controls:22.37%
cases:39.41%
controls:36.53%
81
865
338
3314
96
857
323
3322
96
271
323
3908
55
22
364
4157
85
258
334
3917
109
919
295
3190
147
1379
226
2396
Casts [#/volume] in Urine by Automated count
51483-6 [3030467]
51483-6 [3030467]
-4.8e-01
8.7e-01
2.0e+00
—
2.7e+00
1.4e+00
4.8e-01
cases:1.91%
controls:3.04%
cases:3.58%
controls:1.53%
cases:1.91%
controls:0.26%
—
—
cases:3.58%
controls:0.24%
cases:4.70%
controls:1.22%
cases:7.51%
controls:4.79%
8
127
411
4052
15
64
404
4115
8
11
411
4168
—
15
10
404
4165
19
50
385
4059
28
181
345
3594
Bacteria [Presence] in Urine
87829-8 [36304419]
87829-8 [36304419]
-3.3e-01
8.5e-01
2.1e+00
—
2.7e+00
1.4e+00
6.2e-01
cases:2.15%
controls:2.97%
cases:3.34%
controls:1.46%
cases:1.91%
controls:0.24%
—
—
cases:3.34%
controls:0.24%
cases:4.46%
controls:1.19%
cases:7.77%
controls:4.34%
9
124
410
4055
14
61
405
4118
8
10
411
4169
—
14
10
405
4165
18
49
386
4060
29
164
344
3611
amoxicillin; oral, parenteral
J01CA04 [21602823]
J01CA04 [21602823]
3.8e-01
1.3e+00
2.6e+00
—
1.4e+00
3.5e-01
7.1e-01
cases:24.34%
controls:18.02%
cases:18.85%
controls:5.74%
cases:6.21%
controls:0.48%
—
—
cases:2.39%
controls:0.60%
cases:8.42%
controls:6.06%
cases:34.05%
controls:20.26%
102
753
317
3426
79
240
340
3939
26
20
393
4159
—
10
25
409
4150
34
249
370
3860
127
765
246
3010
erdosteine; oral
R05CB15 [21603394]
R05CB15 [21603394]
1.1e+00
1.7e+00
—
—
—
1.7e+00
1.4e+00
cases:3.34%
controls:1.17%
cases:2.63%
controls:0.50%
—
—
—
—
—
—
cases:2.72%
controls:0.49%
cases:8.04%
controls:2.15%
14
49
405
4130
11
21
408
4158
—
—
—
11
20
393
4089
30
81
343
3694
Myelocytes/Leukocytes in Blood
26498-6 [3017181]
26498-6 [3017181]
—
—
—
—
2.5e+00
1.9e+00
1.5e+00
—
—
—
—
—
—
—
—
cases:1.67%
controls:0.14%
cases:3.71%
controls:0.56%
cases:6.17%
controls:1.48%
—
—
—
—
7
6
412
4169
15
23
389
4086
23
56
350
3719
Urinalysis microscopic panel [#/volume] - Urine by Automated count
50554-5 [3029287]
50554-5 [3029287]
-3.4e-01
8.6e-01
1.9e+00
—
2.7e+00
1.2e+00
5.0e-01
cases:2.86%
controls:3.97%
cases:4.53%
controls:1.96%
cases:2.39%
controls:0.36%
—
—
cases:4.30%
controls:0.29%
cases:5.94%
controls:1.87%
cases:10.19%
controls:6.44%
12
166
407
4013
19
82
400
4097
10
15
409
4164
—
18
12
401
4163
24
77
380
4032
38
243
335
3532
Other polyp of sinus
J33.8 [45591556]
J33.8 [45591556]
2.3e+00
—
—
—
—
—
3.5e+00
cases:1.91%
controls:0.19%
—
—
—
—
—
—
—
—
—
—
cases:4.02%
controls:0.13%
8
8
411
4171
—
—
—
—
—
15
5
358
3770
Neutrophil cytoplasmic Ab [Units/volume] in Serum
5128-4 [3001334]
5128-4 [3001334]
1.7e+00
2.9e+00
1.0e+50
1.0e+50
1.0e+50
—
2.9e+00
cases:1.67%
controls:0.31%
cases:3.34%
controls:0.19%
cases:3.58%
controls:0.00%
cases:1.19%
controls:0.00%
cases:4.77%
controls:0.00%
—
—
cases:5.36%
controls:0.32%
7
13
412
4166
14
8
405
4171
15
0
404
4179
5
0
414
4179
20
0
399
4175
—
20
12
353
3763
Metamyelocytes/Leukocytes in Blood
28541-1 [3002179]
28541-1 [3002179]
—
—
—
—
2.5e+00
1.9e+00
1.4e+00
—
—
—
—
—
—
—
—
cases:1.67%
controls:0.14%
cases:3.22%
controls:0.49%
cases:5.36%
controls:1.40%
—
—
—
—
7
6
412
4169
13
20
391
4089
20
53
353
3722
Promyelocytes/Leukocytes in Blood
26524-9 [3021440]
26524-9 [3021440]
—
—
—
—
2.5e+00
1.8e+00
1.5e+00
—
—
—
—
—
—
—
—
cases:1.67%
controls:0.14%
cases:3.22%
controls:0.56%
cases:5.90%
controls:1.35%
—
—
—
—
7
6
412
4169
13
23
391
4086
22
51
351
3724
Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1742-6 [3006923]
1742-6 [3006923]
3.3e-04
2.1e-01
1.6e+00
2.6e+00
1.6e+00
3.9e-01
1.7e-01
cases:16.47%
controls:16.46%
cases:15.27%
controls:12.80%
cases:10.26%
controls:2.37%
cases:3.10%
controls:0.24%
cases:11.93%
controls:2.61%
cases:19.55%
controls:14.16%
cases:32.98%
controls:29.35%
69
688
350
3491
64
535
355
3644
43
99
376
4080
13
10
406
4169
50
109
369
4066
79
582
325
3527
123
1108
250
2667
acrivastine; oral
R06AX18 [21603518]
R06AX18 [21603518]
6.8e-01
1.2e+00
1.9e+00
—
—
1.0e+00
8.5e-01
cases:10.50%
controls:5.60%
cases:5.49%
controls:1.70%
cases:1.91%
controls:0.29%
—
—
—
—
cases:4.46%
controls:1.61%
cases:12.33%
controls:5.70%
44
234
375
3945
23
71
396
4108
8
12
411
4167
—
—
18
66
386
4043
46
215
327
3560
Infectious Disease
44 [38004484]
44 [38004484]
9.3e-01
2.2e+00
—
1.0e+50
—
2.1e+00
1.4e+00
cases:2.15%
controls:0.86%
cases:3.34%
controls:0.38%
—
—
cases:2.15%
controls:0.00%
—
—
cases:3.71%
controls:0.49%
cases:5.09%
controls:1.32%
9
36
410
4143
14
16
405
4163
—
9
0
410
4179
—
15
20
389
4089
19
50
354
3725
cefalexin; oral
J01DB01 [21602870]
J01DB01 [21602870]
4.6e-01
1.0e+00
1.3e+00
—
1.6e+00
6.0e-01
5.9e-01
cases:34.37%
controls:24.79%
cases:17.66%
controls:7.35%
cases:3.82%
controls:1.08%
—
—
cases:3.34%
controls:0.67%
cases:13.37%
controls:7.81%
cases:39.41%
controls:26.46%
144
1036
275
3143
74
307
345
3872
16
45
403
4134
—
14
28
405
4147
54
321
350
3788
147
999
226
2776
Cortisol [Moles/volume] in Serum or Plasma
14675-3 [3036481]
14675-3 [3036481]
—
1.9e+00
—
—
—
2.7e+00
1.0e+00
—
—
cases:1.67%
controls:0.26%
—
—
—
—
—
—
cases:3.71%
controls:0.27%
cases:3.75%
controls:1.35%
—
7
11
412
4168
—
—
—
15
11
389
4098
14
51
359
3724
sulfamethoxazole and trimethoprim
J01EE01 [21602961]
J01EE01 [21602961]
1.0e+00
1.7e+00
—
—
2.8e+00
2.7e+00
1.3e+00
cases:1.19%
controls:0.43%
cases:1.67%
controls:0.31%
—
—
—
—
cases:1.91%
controls:0.12%
cases:3.22%
controls:0.22%
cases:2.14%
controls:0.61%
5
18
414
4161
7
13
412
4166
—
—
8
5
411
4170
13
9
391
4100
8
23
365
3752
Rheumatology
66 [38004491]
66 [38004491]
6.5e-01
8.3e-01
—
—
2.7e+00
1.5e+00
1.3e+00
cases:4.06%
controls:2.15%
cases:2.39%
controls:1.05%
—
—
—
—
cases:2.39%
controls:0.17%
cases:4.95%
controls:1.14%
cases:8.04%
controls:2.30%
17
90
402
4089
10
44
409
4135
—
—
10
7
409
4168
20
47
384
4062
30
87
343
3688
Myeloperoxidase IgG Ab [Units/volume] in Serum
48404-8 [3049804]
48404-8 [3049804]
—
2.9e+00
1.0e+50
—
1.0e+50
1.0e+50
2.5e+00
—
—
cases:2.15%
controls:0.12%
cases:2.63%
controls:0.00%
—
—
cases:4.77%
controls:0.00%
cases:3.47%
controls:0.00%
cases:2.95%
controls:0.24%
—
9
5
410
4174
11
0
408
4179
—
20
0
399
4175
14
0
390
4109
11
9
362
3766
Blasts/Leukocytes in Blood
26446-5 [3025159]
26446-5 [3025159]
—
—
—
—
2.3e+00
1.6e+00
1.6e+00
—
—
—
—
—
—
—
—
cases:1.43%
controls:0.14%
cases:2.48%
controls:0.54%
cases:5.90%
controls:1.30%
—
—
—
—
6
6
413
4169
10
22
394
4087
22
49
351
3726
Spirometry
127783003 [4133840]
127783003 [4133840]
1.9e+00
—
—
—
—
—
3.5e+00
cases:1.67%
controls:0.26%
—
—
—
—
—
—
—
—
—
—
cases:5.63%
controls:0.19%
7
11
412
4168
—
—
—
—
—
21
7
352
3768
Bronchiectasis
J47 [45605889]
J47 [45605889]
—
—
—
—
—
2.8e+00
2.5e+00
—
—
—
—
—
—
—
—
—
—
cases:1.98%
controls:0.12%
cases:4.02%
controls:0.34%
—
—
—
—
—
8
5
396
4104
15
13
358
3762
Acute bronchitis, unspecified
J20.9 [45562445]
J20.9 [45562445]
7.4e-01
2.4e+00
—
—
—
1.7e+00
1.1e+00
cases:2.86%
controls:1.39%
cases:4.77%
controls:0.43%
—
—
—
—
—
—
cases:1.98%
controls:0.37%
cases:7.51%
controls:2.62%
12
58
407
4121
20
18
399
4161
—
—
—
8
15
396
4094
28
99
345
3676
azelastine; nasal
R01AC03 [21605035]
R01AC03 [21605035]
1.3e+00
1.4e+00
—
—
—
1.6e+00
1.0e+00
cases:5.25%
controls:1.53%
cases:4.06%
controls:1.03%
—
—
—
—
—
—
cases:3.71%
controls:0.80%
cases:7.77%
controls:2.97%
22
64
397
4115
17
43
402
4136
—
—
—
15
33
389
4076
29
112
344
3663
Endoscopic ethmoidectomy
DNB20 [2001301791]
DNB20 [2001301791]
2.3e+00
—
—
—
—
—
2.9e+00
cases:1.67%
controls:0.17%
—
—
—
—
—
—
—
—
—
—
cases:2.41%
controls:0.13%
7
7
412
4172
—
—
—
—
—
9
5
364
3770
esomeprazole; oral, parenteral
A02BC05 [21600100]
A02BC05 [21600100]
6.3e-01
8.6e-01
1.3e+00
—
1.9e+00
1.1e+00
7.2e-01
cases:11.93%
controls:6.70%
cases:8.11%
controls:3.61%
cases:2.39%
controls:0.69%
—
—
cases:5.01%
controls:0.77%
cases:10.15%
controls:3.65%
cases:14.48%
controls:7.63%
50
280
369
3899
34
151
385
4028
10
29
409
4150
—
21
32
398
4143
41
150
363
3959
54
288
319
3487
fluticasone, combinations
R01AD58 [43534837]
R01AD58 [43534837]
1.2e+00
1.4e+00
—
—
—
1.6e+00
1.0e+00
cases:5.01%
controls:1.53%
cases:4.06%
controls:1.03%
—
—
—
—
—
—
cases:3.71%
controls:0.80%
cases:7.77%
controls:2.94%
21
64
398
4115
17
43
402
4136
—
—
—
15
33
389
4076
29
111
344
3664
Nuclear Ab [Titer] in Serum
29953-7 [3037522]
29953-7 [3037522]
9.7e-01
2.1e+00
1.0e+50
—
—
2.0e+00
1.1e+00
cases:2.86%
controls:1.10%
cases:2.63%
controls:0.34%
cases:2.39%
controls:0.00%
—
—
—
—
cases:1.73%
controls:0.24%
cases:4.29%
controls:1.43%
12
46
407
4133
11
14
408
4165
10
0
409
4179
—
—
7
10
397
4099
16
54
357
3721
Pleural effusion, not elsewhere classified
J90 [45605897]
J90 [45605897]
2.0e+00
2.8e+00
1.0e+50
1.0e+50
1.0e+50
—
2.3e+00
cases:1.19%
controls:0.17%
cases:2.39%
controls:0.14%
cases:2.15%
controls:0.00%
cases:1.43%
controls:0.00%
cases:1.19%
controls:0.00%
—
—
cases:1.61%
controls:0.16%
5
7
414
4172
10
6
409
4173
9
0
410
4179
6
0
413
4179
5
0
414
4175
—
6
6
367
3769
Tissue Pathology biopsy report
66121-5 [40768804]
66121-5 [40768804]
-1.3e-01
5.8e-01
2.0e+00
—
3.2e+00
9.7e-01
4.9e-01
cases:3.82%
controls:4.31%
cases:3.34%
controls:1.89%
cases:1.67%
controls:0.24%
—
—
cases:2.86%
controls:0.12%
cases:3.47%
controls:1.34%
cases:8.31%
controls:5.25%
16
180
403
3999
14
79
405
4100
7
10
412
4169
—
12
5
407
4170
14
55
390
4054
31
198
342
3577
Inpatient Visit
IP [9201]
IP [9201]
3.6e-01
7.4e-01
2.1e+00
1.0e+50
2.0e+00
1.0e+00
1.4e-01
cases:9.31%
controls:6.70%
cases:4.53%
controls:2.23%
cases:1.67%
controls:0.22%
cases:7.64%
controls:0.00%
cases:2.15%
controls:0.29%
cases:5.20%
controls:1.95%
cases:6.70%
controls:5.85%
39
280
380
3899
19
93
400
4086
7
9
412
4170
32
0
387
4179
9
12
410
4163
21
80
383
4029
25
221
348
3554
General Practice
1 [38004446]
1 [38004446]
3.0e-01
9.3e-01
2.2e+00
—
1.7e+00
6.3e-01
3.0e-01
cases:11.69%
controls:8.97%
cases:10.74%
controls:4.52%
cases:5.01%
controls:0.57%
—
—
cases:3.34%
controls:0.60%
cases:8.66%
controls:4.82%
cases:19.30%
controls:15.07%
49
375
370
3804
45
189
374
3990
21
24
398
4155
—
14
25
405
4150
35
198
369
3911
72
569
301
3206
Case Management Agency
251B00000X [38004193]
251B00000X [38004193]
8.4e-02
2.6e-01
8.3e-01
3.0e+00
5.8e-01
4.4e-01
2.9e-01
cases:44.87%
controls:42.81%
cases:40.81%
controls:34.67%
cases:25.54%
controls:13.02%
cases:12.65%
controls:0.69%
cases:21.72%
controls:13.46%
cases:48.27%
controls:37.62%
cases:65.68%
controls:58.94%
188
1789
231
2390
171
1449
248
2730
107
544
312
3635
53
29
366
4150
91
562
328
3613
195
1546
209
2563
245
2225
128
1550
Other specified chronic obstructive pulmonary disease
J44.8 [45586673]
J44.8 [45586673]
7.8e-01
1.6e+00
—
—
1.9e+00
1.4e+00
6.8e-01
cases:2.86%
controls:1.34%
cases:3.58%
controls:0.77%
—
—
—
—
cases:1.67%
controls:0.26%
cases:4.46%
controls:1.12%
cases:4.29%
controls:2.23%
12
56
407
4123
15
32
404
4147
—
—
7
11
412
4164
18
46
386
4063
16
84
357
3691
Angiotensin converting enzyme [Enzymatic activity/volume] in Serum or Plasma
2742-5 [3034780]
2742-5 [3034780]
1.4e+00
2.3e+00
—
—
1.0e+50
2.5e+00
1.1e+00
cases:1.91%
controls:0.45%
cases:1.91%
controls:0.19%
—
—
—
—
cases:1.19%
controls:0.00%
cases:1.49%
controls:0.12%
cases:1.34%
controls:0.45%
8
19
411
4160
8
8
411
4171
—
—
5
0
414
4175
6
5
398
4104
5
17
368
3758
Bacteria [#/volume] in Urine by Automated count
51480-2 [3031040]
51480-2 [3031040]
5.4e-04
7.6e-01
2.0e+00
—
2.1e+00
4.2e-01
3.0e-01
cases:7.64%
controls:7.63%
cases:8.35%
controls:4.09%
cases:4.53%
controls:0.65%
—
—
cases:4.53%
controls:0.60%
cases:6.44%
controls:4.33%
cases:16.62%
controls:12.87%
32
319
387
3860
35
171
384
4008
19
27
400
4152
—
19
25
400
4150
26
178
378
3931
62
486
311
3289
Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction
14804-9 [3022250]
14804-9 [3022250]
9.0e-01
7.3e-01
2.3e+00
—
2.5e+00
7.5e-01
5.0e-01
cases:2.15%
controls:0.89%
cases:1.67%
controls:0.81%
cases:1.67%
controls:0.17%
—
—
cases:1.43%
controls:0.12%
cases:1.49%
controls:0.71%
cases:2.68%
controls:1.64%
9
37
410
4142
7
34
412
4145
7
7
412
4172
—
6
5
413
4170
6
29
398
4080
10
62
363
3713
Puncture of maxillary antrum
TDM10 [2001301819]
TDM10 [2001301819]
2.3e+00
—
—
—
—
—
2.4e+00
cases:1.43%
controls:0.14%
—
—
—
—
—
—
—
—
—
—
cases:3.49%
controls:0.32%
6
6
413
4173
—
—
—
—
—
13
12
360
3763
sulfadiazine and trimethoprim
J01EE02 [21602962]
J01EE02 [21602962]
7.0e-01
1.6e+00
—
—
—
1.9e+00
1.1e+00
cases:5.25%
controls:2.68%
cases:3.82%
controls:0.77%
—
—
—
—
—
—
cases:4.70%
controls:0.71%
cases:8.04%
controls:2.75%
22
112
397
4067
16
32
403
4147
—
—
—
19
29
385
4080
30
104
343
3671
IgM [Mass/volume] in Serum or Plasma
2472-9 [3028026]
2472-9 [3028026]
1.1e+00
2.2e+00
—
—
—
2.5e+00
1.2e+00
cases:1.43%
controls:0.50%
cases:1.43%
controls:0.17%
—
—
—
—
—
—
cases:1.73%
controls:0.15%
cases:2.41%
controls:0.72%
6
21
413
4158
6
7
413
4172
—
—
—
7
6
397
4103
9
27
364
3748
Left sided colitis
K51.5 [45533604]
K51.5 [45533604]
—
—
—
—
—
2.3e+00
2.2e+00
—
—
—
—
—
—
—
—
—
—
cases:1.73%
controls:0.17%
cases:2.14%
controls:0.24%
—
—
—
—
—
7
7
397
4102
8
9
365
3766
Other specified special examinations
Z01.8 [45581003]
Z01.8 [45581003]
1.0e+00
1.3e+00
—
—
—
2.2e+00
1.3e+00
cases:5.01%
controls:1.89%
cases:2.15%
controls:0.60%
—
—
—
—
—
—
cases:4.95%
controls:0.58%
cases:9.92%
controls:2.78%
21
79
398
4100
9
25
410
4154
—
—
—
20
24
384
4085
37
105
336
3670
Complement C3 [Mass/volume] in Serum or Plasma
4485-9 [3000620]
4485-9 [3000620]
1.6e+00
2.3e+00
—
—
1.0e+50
—
2.2e+00
cases:1.19%
controls:0.24%
cases:1.43%
controls:0.14%
—
—
—
—
cases:1.19%
controls:0.00%
—
—
cases:2.14%
controls:0.24%
5
10
414
4169
6
6
413
4173
—
—
5
0
414
4175
—
8
9
365
3766
Complement C4 [Mass/volume] in Serum or Plasma
4498-2 [3017766]
4498-2 [3017766]
1.6e+00
2.3e+00
—
—
1.0e+50
—
2.2e+00
cases:1.19%
controls:0.24%
cases:1.43%
controls:0.14%
—
—
—
—
cases:1.19%
controls:0.00%
—
—
cases:2.14%
controls:0.24%
5
10
414
4169
6
6
413
4173
—
—
5
0
414
4175
—
8
9
365
3766
pseudoephedrine, combinations; oral
R01BA52 [21603213]
R01BA52 [21603213]
6.8e-01
1.1e+00
2.0e+00
—
—
7.9e-01
7.1e-01
cases:15.04%
controls:8.26%
cases:6.68%
controls:2.30%
cases:3.34%
controls:0.45%
—
—
—
—
cases:4.70%
controls:2.19%
cases:15.28%
controls:8.13%
63
345
356
3834
28
96
391
4083
14
19
405
4160
—
—
19
90
385
4019
57
307
316
3468
pH of Urine
2756-5 [3015736]
2756-5 [3015736]
5.1e-02
6.2e-01
2.0e+00
—
2.5e+00
3.4e-01
2.0e-01
cases:4.30%
controls:4.09%
cases:4.06%
controls:2.23%
cases:2.15%
controls:0.29%
—
—
cases:3.10%
controls:0.26%
cases:3.71%
controls:2.68%
cases:9.92%
controls:8.24%
18
171
401
4008
17
93
402
4086
9
12
410
4167
—
13
11
406
4164
15
110
389
3999
37
311
336
3464
Functional endoscopic opening of maxillary antrum
DMB20 [2001301780]
DMB20 [2001301780]
1.9e+00
—
—
—
—
—
2.6e+00
cases:2.63%
controls:0.38%
—
—
—
—
—
—
—
—
—
—
cases:4.02%
controls:0.32%
11
16
408
4163
—
—
—
—
—
15
12
358
3763
budesonide; nasal
R01AD05 [21605047]
R01AD05 [21605047]
2.0e+00
—
—
—
—
—
2.5e+00
cases:2.15%
controls:0.29%
—
—
—
—
—
—
—
—
—
—
cases:1.88%
controls:0.16%
9
12
410
4167
—
—
—
—
—
7
6
366
3769
DNA double strand Ab [Units/volume] in Serum
5130-0 [3023420]
5130-0 [3023420]
—
2.3e+00
—
—
—
—
2.2e+00
—
—
cases:1.43%
controls:0.14%
—
—
—
—
—
—
—
—
cases:1.61%
controls:0.19%
—
6
6
413
4173
—
—
—
—
6
7
367
3768
Osmolality of Urine
2695-5 [3026782]
2695-5 [3026782]
-5.8e-01
6.4e-01
2.3e+00
—
2.2e+00
1.1e+00
7.2e-01
cases:1.43%
controls:2.54%
cases:2.15%
controls:1.15%
cases:1.67%
controls:0.17%
—
—
cases:1.43%
controls:0.17%
cases:2.97%
controls:0.97%
cases:6.43%
controls:3.23%
6
106
413
4073
9
48
410
4131
7
7
412
4172
—
6
7
413
4168
12
40
392
4069
24
122
349
3653
Gastroenterology
10 [38004455]
10 [38004455]
1.0e+00
1.2e+00
1.5e+00
—
1.7e+00
1.4e+00
8.6e-01
cases:7.64%
controls:2.92%
cases:4.06%
controls:1.32%
cases:1.19%
controls:0.26%
—
—
cases:1.19%
controls:0.22%
cases:5.69%
controls:1.41%
cases:9.92%
controls:4.45%
32
122
387
4057
17
55
402
4124
5
11
414
4168
—
5
9
414
4166
23
58
381
4051
37
168
336
3607
Glucose [Presence] in Urine by Test strip
25428-4 [3009261]
25428-4 [3009261]
-6.1e-02
5.6e-01
2.2e+00
—
2.3e+00
1.8e-01
2.5e-01
cases:5.01%
controls:5.31%
cases:5.25%
controls:3.06%
cases:2.63%
controls:0.31%
—
—
cases:4.06%
controls:0.43%
cases:4.46%
controls:3.75%
cases:12.87%
controls:10.36%
21
222
398
3957
22
128
397
4051
11
13
408
4166
—
17
18
402
4157
18
154
386
3955
48
391
325
3384
Ketones [Presence] in Urine by Test strip
2514-8 [3035350]
2514-8 [3035350]
-2.8e-03
5.6e-01
2.2e+00
—
2.3e+00
2.6e-01
1.8e-01
cases:5.25%
controls:5.26%
cases:5.25%
controls:3.06%
cases:2.63%
controls:0.31%
—
—
cases:4.06%
controls:0.43%
cases:4.70%
controls:3.67%
cases:12.06%
controls:10.30%
22
220
397
3959
22
128
397
4051
11
13
408
4166
—
17
18
402
4157
19
151
385
3958
45
389
328
3386
Nitrite [Presence] in Urine by Test strip
5802-4 [3021601]
5802-4 [3021601]
-6.4e-02
5.2e-01
2.2e+00
—
2.3e+00
2.1e-01
2.1e-01
cases:4.77%
controls:5.07%
cases:5.01%
controls:3.04%
cases:2.63%
controls:0.31%
—
—
cases:4.06%
controls:0.43%
cases:4.46%
controls:3.65%
cases:12.06%
controls:10.01%
20
212
399
3967
21
127
398
4052
11
13
408
4166
—
17
18
402
4157
18
150
386
3959
45
378
328
3397
Albumin [Presence] in Urine by Test strip
50949-7 [3029937]
50949-7 [3029937]
-2.2e-01
6.5e-01
2.5e+00
—
1.9e+00
5.1e-01
2.8e-01
cases:2.63%
controls:3.25%
cases:2.63%
controls:1.39%
cases:1.67%
controls:0.14%
—
—
cases:1.91%
controls:0.29%
cases:2.72%
controls:1.65%
cases:6.97%
controls:5.35%
11
136
408
4043
11
58
408
4121
7
6
412
4173
—
8
12
411
4163
11
68
393
4041
26
202
347
3573
Urinalysis macro (dipstick) panel - Urine
24357-6 [3037467]
24357-6 [3037467]
-9.4e-02
5.4e-01
1.9e+00
—
2.4e+00
4.0e-01
3.7e-01
cases:7.64%
controls:8.33%
cases:7.16%
controls:4.31%
cases:4.77%
controls:0.72%
—
—
cases:6.21%
controls:0.57%
cases:7.67%
controls:5.26%
cases:18.50%
controls:13.51%
32
348
387
3831
30
180
389
3999
20
30
399
4149
—
26
24
393
4151
31
216
373
3893
69
510
304
3265
beclometasone; inhalant
R03BA01 [21603284]
R03BA01 [21603284]
7.2e-01
7.8e-01
—
—
1.7e+00
1.4e+00
1.2e+00
cases:5.01%
controls:2.51%
cases:3.34%
controls:1.56%
—
—
—
—
cases:1.91%
controls:0.36%
cases:5.69%
controls:1.41%
cases:8.04%
controls:2.54%
21
105
398
4074
14
65
405
4114
—
—
8
15
411
4160
23
58
381
4051
30
96
343
3679
Emergency Medicine
93 [38004510]
93 [38004510]
2.7e-01
9.9e-01
2.5e+00
1.0e+50
9.6e-01
8.5e-01
3.5e-01
cases:8.59%
controls:6.68%
cases:9.31%
controls:3.69%
cases:5.49%
controls:0.48%
cases:3.34%
controls:0.00%
cases:1.43%
controls:0.55%
cases:9.16%
controls:4.11%
cases:18.23%
controls:13.59%
36
279
383
3900
39
154
380
4025
23
20
396
4159
14
0
405
4179
6
23
413
4152
37
169
367
3940
68
513
305
3262
lansoprazole; oral
A02BC03 [21600098]
A02BC03 [21600098]
5.7e-01
8.6e-01
—
—
2.1e+00
1.3e+00
3.6e-01
cases:7.40%
controls:4.31%
cases:4.77%
controls:2.08%
—
—
—
—
cases:4.77%
controls:0.62%
cases:7.43%
controls:2.07%
cases:6.97%
controls:4.98%
31
180
388
3999
20
87
399
4092
—
—
20
26
399
4149
30
85
374
4024
26
188
347
3587
Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma
33762-6 [3029187]
33762-6 [3029187]
2.8e-01
7.9e-01
2.7e+00
1.0e+50
—
1.5e+00
3.3e-01
cases:3.10%
controls:2.37%
cases:3.82%
controls:1.77%
cases:2.15%
controls:0.14%
cases:1.67%
controls:0.00%
—
—
cases:5.45%
controls:1.29%
cases:7.24%
controls:5.32%
13
99
406
4080
16
74
403
4105
9
6
410
4173
7
0
412
4179
—
22
53
382
4056
27
201
346
3574
cetirizine; oral
R06AE07 [21603497]
R06AE07 [21603497]
9.6e-01
1.4e+00
1.4e+00
—
—
9.6e-01
8.4e-01
cases:14.08%
controls:5.89%
cases:10.26%
controls:2.66%
cases:1.67%
controls:0.41%
—
—
—
—
cases:7.18%
controls:2.87%
cases:15.01%
controls:7.07%
59
246
360
3933
43
111
376
4068
7
17
412
4162
—
—
29
118
375
3991
56
267
317
3508
clarithromycin; oral, parenteral
J01FA09 [21602977]
J01FA09 [21602977]
8.0e-01
1.6e+00
—
—
—
1.7e+00
5.4e-01
cases:8.11%
controls:3.80%
cases:5.01%
controls:1.01%
—
—
—
—
—
—
cases:2.97%
controls:0.54%
cases:5.63%
controls:3.36%
34
159
385
4020
21
42
398
4137
—
—
—
12
22
392
4087
21
127
352
3648
risedronic acid; oral
M05BA07 [21604155]
M05BA07 [21604155]
—
—
—
—
—
2.0e+00
2.1e+00
—
—
—
—
—
—
—
—
—
—
cases:1.73%
controls:0.24%
cases:2.95%
controls:0.37%
—
—
—
—
—
7
10
397
4099
11
14
362
3761
Rhinopharyngoscopy
UDH02 [2001301680]
UDH02 [2001301680]
1.9e+00
2.1e+00
—
—
—
—
2.1e+00
cases:2.63%
controls:0.38%
cases:1.19%
controls:0.14%
—
—
—
—
—
—
—
—
cases:3.22%
controls:0.40%
11
16
408
4163
5
6
414
4173
—
—
—
—
12
15
361
3760
Status asthmaticus
J46 [45591560]
J46 [45591560]
1.9e+00
—
—
—
—
—
2.1e+00
cases:2.15%
controls:0.31%
—
—
—
—
—
—
—
—
—
—
cases:2.14%
controls:0.26%
9
13
410
4166
—
—
—
—
—
8
10
365
3765
Thoracic and Cardiac Surgery
OMOP4822009 [45756830]
OMOP4822009 [45756830]
9.3e-01
—
—
—
—
2.3e+00
1.7e+00
cases:2.15%
controls:0.86%
—
—
—
—
—
—
—
—
cases:2.97%
controls:0.29%
cases:3.49%
controls:0.66%
9
36
410
4143
—
—
—
—
12
12
392
4097
13
25
360
3750
Chronic rhinitis
J31.0 [45572165]
J31.0 [45572165]
1.2e+00
—
—
—
—
2.3e+00
1.7e+00
cases:1.43%
controls:0.43%
—
—
—
—
—
—
—
—
cases:1.73%
controls:0.17%
cases:3.75%
controls:0.72%
6
18
413
4161
—
—
—
—
7
7
397
4102
14
27
359
3748
Leukocyte esterase [Presence] in Urine by Automated test strip
60026-2 [40763086]
60026-2 [40763086]
-8.5e-02
3.2e-01
2.2e+00
—
1.8e+00
-1.1e-01
3.1e-01
cases:4.06%
controls:4.40%
cases:3.34%
controls:2.44%
cases:2.15%
controls:0.24%
—
—
cases:1.91%
controls:0.34%
cases:2.72%
controls:3.02%
cases:10.72%
controls:8.13%
17
184
402
3995
14
102
405
4077
9
10
410
4169
—
8
14
411
4161
11
124
393
3985
40
307
333
3468
Paranasal sinuses X-ray examination in one projection
DM1QA [2001301761]
DM1QA [2001301761]
1.8e+00
—
—
1.0e+50
—
—
2.1e+00
cases:1.67%
controls:0.29%
—
—
—
—
cases:1.67%
controls:0.00%
—
—
—
—
cases:3.22%
controls:0.40%
7
12
412
4167
—
—
7
0
412
4179
—
—
12
15
361
3760
fluconazole; oral, parenteral
J02AC01 [21603080]
J02AC01 [21603080]
5.4e-01
5.6e-01
2.2e+00
—
1.7e+00
7.4e-01
5.9e-01
cases:10.26%
controls:6.22%
cases:3.82%
controls:2.23%
cases:1.67%
controls:0.19%
—
—
cases:2.15%
controls:0.41%
cases:4.21%
controls:2.04%
cases:10.46%
controls:6.09%
43
260
376
3919
16
93
403
4086
7
8
412
4171
—
9
17
410
4158
17
84
387
4025
39
230
334
3545
azathioprine; oral, parenteral
L04AX01 [21603927]
L04AX01 [21603927]
—
—
—
—
—
—
3.9e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.97%
controls:0.16%
—
—
—
—
—
—
26
6
347
3769
Cough
R05 [45606792]
R05 [45606792]
1.1e+00
2.7e+00
—
—
—
—
8.0e-01
cases:4.77%
controls:1.65%
cases:6.21%
controls:0.43%
—
—
—
—
—
—
—
—
cases:5.09%
controls:2.36%
20
69
399
4110
26
18
393
4161
—
—
—
—
19
89
354
3686
Albumin [Mass/volume] in Serum or Plasma
1751-7 [3024561]
1751-7 [3024561]
1.4e-01
8.5e-01
1.3e+00
—
2.0e+00
8.8e-01
3.6e-01
cases:4.77%
controls:4.19%
cases:5.97%
controls:2.63%
cases:1.91%
controls:0.55%
—
—
cases:2.86%
controls:0.38%
cases:6.19%
controls:2.65%
cases:11.53%
controls:8.32%
20
175
399
4004
25
110
394
4069
8
23
411
4156
—
12
16
407
4159
25
109
379
4000
43
314
330
3461
Troponin I.cardiac [Mass/volume] in Serum or Plasma
10839-9 [3021337]
10839-9 [3021337]
-1.7e-01
7.6e-01
—
—
2.6e+00
1.2e+00
-1.9e-01
cases:1.43%
controls:1.70%
cases:2.86%
controls:1.36%
—
—
—
—
cases:2.15%
controls:0.17%
cases:3.22%
controls:1.00%
cases:3.22%
controls:3.87%
6
71
413
4108
12
57
407
4122
—
—
9
7
410
4168
13
41
391
4068
12
146
361
3629
Intravenous
ZX120 [2001311495]
ZX120 [2001311495]
—
1.8e+00
—
—
—
2.2e+00
1.5e+00
—
—
cases:1.19%
controls:0.19%
—
—
—
—
—
—
cases:1.98%
controls:0.22%
cases:3.75%
controls:0.87%
—
5
8
414
4171
—
—
—
8
9
396
4100
14
33
359
3742
Physiotherapy
R4110 [2001310233]
R4110 [2001310233]
2.7e-01
1.1e+00
2.1e+00
—
—
1.5e+00
1.1e+00
cases:3.82%
controls:2.94%
cases:3.34%
controls:1.17%
cases:1.19%
controls:0.14%
—
—
—
—
cases:4.95%
controls:1.14%
cases:8.85%
controls:3.18%
16
123
403
4056
14
49
405
4130
5
6
414
4173
—
—
20
47
384
4062
33
120
340
3655
ECG with 12 standard connections
XF400 [2001303368]
XF400 [2001303368]
-1.3e-01
1.9e+00
—
—
—
1.7e+00
3.4e-01
cases:1.43%
controls:1.63%
cases:2.86%
controls:0.43%
—
—
—
—
—
—
cases:2.23%
controls:0.41%
cases:2.14%
controls:1.54%
6
68
413
4111
12
18
407
4161
—
—
—
9
17
395
4092
8
58
365
3717
Dyspnoea
R06.0 [45558449]
R06.0 [45558449]
3.9e-01
1.6e+00
2.0e+00
1.0e+50
—
9.3e-01
7.2e-01
cases:3.82%
controls:2.61%
cases:4.53%
controls:0.98%
cases:1.43%
controls:0.19%
cases:1.91%
controls:0.00%
—
—
cases:2.97%
controls:1.19%
cases:7.24%
controls:3.66%
16
109
403
4070
19
41
400
4138
6
8
413
4171
8
0
411
4179
—
12
49
392
4060
27
138
346
3637
ipratropium bromide; inhalant
R03BB01 [21603293]
R03BB01 [21603293]
1.8e+00
1.7e+00
—
—
—
1.6e+00
1.8e+00
cases:2.15%
controls:0.36%
cases:1.67%
controls:0.31%
—
—
—
—
—
—
cases:1.73%
controls:0.34%
cases:3.49%
controls:0.61%
9
15
410
4164
7
13
412
4166
—
—
—
7
14
397
4095
13
23
360
3752
Psychiatry
26 [38004469]
26 [38004469]
2.4e-01
3.4e-01
9.2e-01
—
1.5e+00
1.3e+00
7.3e-01
cases:5.01%
controls:4.00%
cases:2.63%
controls:1.89%
cases:1.67%
controls:0.67%
—
—
cases:2.63%
controls:0.62%
cases:6.19%
controls:1.73%
cases:7.77%
controls:3.92%
21
167
398
4012
11
79
408
4100
7
28
412
4151
—
11
26
408
4149
25
71
379
4038
29
148
344
3627
Cardiology
6 [38004451]
6 [38004451]
1.3e-01
2.3e-01
1.3e+00
—
1.8e+00
1.1e+00
5.3e-01
cases:7.88%
controls:7.01%
cases:5.49%
controls:4.43%
cases:2.15%
controls:0.60%
—
—
cases:2.63%
controls:0.43%
cases:9.65%
controls:3.43%
cases:15.55%
controls:9.75%
33
293
386
3886
23
185
396
3994
9
25
410
4154
—
11
18
408
4157
39
141
365
3968
58
368
315
3407
High resolution CT examination of lungs
GD1DD [2001303632]
GD1DD [2001303632]
1.6e+00
—
—
—
1.0e+50
—
3.4e+00
cases:1.19%
controls:0.24%
—
—
—
—
—
—
cases:1.19%
controls:0.00%
—
—
cases:6.70%
controls:0.24%
5
10
414
4169
—
—
—
5
0
414
4175
—
25
9
348
3766
ranitidine bismuth citrate; oral
A02BA07 [21600088]
A02BA07 [21600088]
4.5e-01
4.6e-01
—
—
2.1e+00
1.3e+00
8.7e-01
cases:3.58%
controls:2.32%
cases:1.43%
controls:0.91%
—
—
—
—
cases:1.67%
controls:0.22%
cases:2.97%
controls:0.80%
cases:5.09%
controls:2.20%
15
97
404
4082
6
38
413
4141
—
—
7
9
412
4166
12
33
392
4076
19
83
354
3692
ranitidine; oral, parenteral
A02BA02 [21600083]
A02BA02 [21600083]
4.5e-01
4.6e-01
—
—
2.1e+00
1.3e+00
8.7e-01
cases:3.58%
controls:2.32%
cases:1.43%
controls:0.91%
—
—
—
—
cases:1.67%
controls:0.22%
cases:2.97%
controls:0.80%
cases:5.09%
controls:2.20%
15
97
404
4082
6
38
413
4141
—
—
7
9
412
4166
12
33
392
4076
19
83
354
3692
Influenza virus A RNA [Presence] in Specimen by NAA with probe detection
34487-9 [3044938]
34487-9 [3044938]
4.2e-01
1.7e+00
—
1.0e+50
—
1.6e+00
2.6e-01
cases:1.67%
controls:1.10%
cases:3.82%
controls:0.69%
—
—
cases:2.15%
controls:0.00%
—
—
cases:2.72%
controls:0.54%
cases:3.22%
controls:2.49%
7
46
412
4133
16
29
403
4150
—
9
0
410
4179
—
11
22
393
4087
12
94
361
3681
Physiotherapist
Z3226 [2001311560]
Z3226 [2001311560]
5.5e-01
1.6e+00
—
—
—
1.9e+00
1.5e+00
cases:2.63%
controls:1.53%
cases:1.67%
controls:0.36%
—
—
—
—
—
—
cases:3.22%
controls:0.51%
cases:6.17%
controls:1.48%
11
64
408
4115
7
15
412
4164
—
—
—
13
21
391
4088
23
56
350
3719
Acute maxillary sinusitis
J01.0 [45601112]
J01.0 [45601112]
5.3e-01
1.8e+00
—
1.0e+50
—
1.5e+00
7.2e-01
cases:3.34%
controls:1.99%
cases:3.34%
controls:0.57%
—
—
cases:1.19%
controls:0.00%
—
—
cases:4.21%
controls:0.92%
cases:5.36%
controls:2.68%
14
83
405
4096
14
24
405
4155
—
5
0
414
4179
—
17
38
387
4071
20
101
353
3674
mesalazine; oral, rectal
A07EC02 [21600664]
A07EC02 [21600664]
1.4e+00
1.9e+00
—
—
—
1.4e+00
1.4e+00
cases:2.15%
controls:0.53%
cases:2.63%
controls:0.41%
—
—
—
—
—
—
cases:2.23%
controls:0.56%
cases:2.68%
controls:0.66%
9
22
410
4157
11
17
408
4162
—
—
—
9
23
395
4086
10
25
363
3750
HIV 1 and 2 tests - Meaningful Use set
75622-1 [46235355]
75622-1 [46235355]
3.0e-01
2.1e+00
—
—
—
1.3e+00
1.2e+00
cases:1.67%
controls:1.24%
cases:3.10%
controls:0.41%
—
—
—
—
—
—
cases:1.49%
controls:0.39%
cases:4.83%
controls:1.51%
7
52
412
4127
13
17
406
4162
—
—
—
6
16
398
4093
18
57
355
3718
SARS-CoV-2 (COVID-19) RNA [Presence] in Respiratory system specimen by NAA with probe detection
94500-6 [706163]
94500-6 [706163]
2.2e-01
8.9e-01
2.3e+00
1.0e+50
1.5e+00
7.5e-01
2.7e-01
cases:4.30%
controls:3.49%
cases:4.77%
controls:2.01%
cases:2.63%
controls:0.26%
cases:1.91%
controls:0.00%
cases:1.43%
controls:0.34%
cases:4.95%
controls:2.41%
cases:9.92%
controls:7.76%
18
146
401
4033
20
84
399
4095
11
11
408
4168
8
0
411
4179
6
14
413
4161
20
99
384
4010
37
293
336
3482
Emergency Room and Inpatient Visit
ERIP [262]
ERIP [262]
5.0e-01
1.1e+00
2.1e+00
1.0e+50
—
9.2e-01
4.4e-01
cases:3.58%
controls:2.20%
cases:4.77%
controls:1.68%
cases:2.15%
controls:0.26%
cases:5.01%
controls:0.00%
—
—
cases:3.47%
controls:1.41%
cases:8.85%
controls:5.88%
15
92
404
4087
20
70
399
4109
9
11
410
4168
21
0
398
4179
—
14
58
390
4051
33
222
340
3553
Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma
2324-2 [3026910]
2324-2 [3026910]
1.7e-01
3.4e-01
1.6e+00
—
1.6e+00
5.0e-01
2.7e-01
cases:8.35%
controls:7.15%
cases:4.30%
controls:3.09%
cases:2.15%
controls:0.45%
—
—
cases:2.15%
controls:0.43%
cases:5.94%
controls:3.67%
cases:15.01%
controls:11.92%
35
299
384
3880
18
129
401
4050
9
19
410
4160
—
9
18
410
4157
24
151
380
3958
56
450
317
3325
Measurement of bone density from two or more locations with X-ray
NK6QA [2001308500]
NK6QA [2001308500]
—
—
—
—
—
—
3.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:8.31%
controls:0.37%
—
—
—
—
—
—
31
14
342
3761
Bacteria identified in Blood by Culture
600-7 [3023368]
600-7 [3023368]
-1.7e-01
2.0e+00
—
1.0e+50
1.9e+00
1.2e+00
5.5e-01
cases:1.91%
controls:2.25%
cases:6.92%
controls:1.01%
—
—
cases:2.15%
controls:0.00%
cases:1.43%
controls:0.22%
cases:3.47%
controls:1.07%
cases:7.24%
controls:4.29%
8
94
411
4085
29
42
390
4137
—
9
0
410
4179
6
9
413
4166
14
44
390
4065
27
162
346
3613
Nephrology
39 [38004479]
39 [38004479]
8.7e-01
1.0e+00
—
—
—
1.6e+00
1.5e+00
cases:1.19%
controls:0.50%
cases:1.43%
controls:0.53%
—
—
—
—
—
—
cases:2.72%
controls:0.54%
cases:3.22%
controls:0.77%
5
21
414
4158
6
22
413
4157
—
—
—
11
22
393
4087
12
29
361
3746
azithromycin; oral, parenteral
J01FA10 [21602978]
J01FA10 [21602978]
9.1e-01
1.4e+00
1.4e+00
—
—
7.8e-01
7.4e-01
cases:19.09%
controls:8.64%
cases:8.11%
controls:2.06%
cases:1.19%
controls:0.29%
—
—
—
—
cases:5.45%
controls:2.58%
cases:16.09%
controls:8.34%
80
361
339
3818
34
86
385
4093
5
12
414
4167
—
—
22
106
382
4003
60
315
313
3460
mycophenolic acid; oral, parenteral
L04AA06 [21603896]
L04AA06 [21603896]
—
—
—
—
—
—
3.0e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.68%
controls:0.13%
—
—
—
—
—
—
10
5
363
3770
fenoterol and ipratropium bromide
R03AL01 [43534843]
R03AL01 [43534843]
3.0e-01
1.6e+00
—
—
—
9.4e-01
1.4e+00
cases:1.19%
controls:0.89%
cases:2.39%
controls:0.48%
—
—
—
—
—
—
cases:1.24%
controls:0.49%
cases:3.22%
controls:0.82%
5
37
414
4142
10
20
409
4159
—
—
—
5
20
399
4089
12
31
361
3744
beclometasone; nasal
R01AD01 [21605043]
R01AD01 [21605043]
1.4e+00
1.6e+00
—
—
—
7.9e-01
9.7e-01
cases:5.25%
controls:1.39%
cases:2.39%
controls:0.48%
—
—
—
—
—
—
cases:1.49%
controls:0.68%
cases:2.68%
controls:1.03%
22
58
397
4121
10
20
409
4159
—
—
—
6
28
398
4081
10
39
363
3736
Bacteria identified in Isolate by Culture
43409-2 [3042936]
43409-2 [3042936]
2.4e-01
1.5e+00
1.0e+50
—
—
1.4e+00
6.2e-01
cases:1.67%
controls:1.32%
cases:2.86%
controls:0.62%
cases:2.39%
controls:0.00%
—
—
—
—
cases:2.48%
controls:0.61%
cases:3.49%
controls:1.91%
7
55
412
4124
12
26
407
4153
10
0
409
4179
—
—
10
25
394
4084
13
72
360
3703
Spirometry study
18759-1 [3000492]
18759-1 [3000492]
1.4e+00
1.8e+00
—
—
—
—
1.6e+00
cases:2.86%
controls:0.74%
cases:1.19%
controls:0.19%
—
—
—
—
—
—
—
—
cases:4.02%
controls:0.85%
12
31
407
4148
5
8
414
4171
—
—
—
—
15
32
358
3743
formoterol and fluticasone
R03AK11 [44819166]
R03AK11 [44819166]
2.3e+00
—
—
—
—
—
2.9e+00
cases:1.19%
controls:0.12%
—
—
—
—
—
—
—
—
—
—
cases:2.41%
controls:0.13%
5
5
414
4174
—
—
—
—
—
9
5
364
3770
Myeloperoxidase Ab [Units/volume] in Serum
6969-0 [3023150]
6969-0 [3023150]
—
—
—
1.0e+50
—
—
2.9e+00
—
—
—
—
—
—
cases:1.19%
controls:0.00%
—
—
—
—
cases:2.41%
controls:0.13%
—
—
—
5
0
414
4179
—
—
9
5
364
3770
furosemide; oral, parenteral
C03CA01 [21601518]
C03CA01 [21601518]
1.6e-01
2.1e-01
5.9e-01
—
1.3e+00
8.0e-01
7.3e-01
cases:5.97%
controls:5.12%
cases:5.49%
controls:4.50%
cases:2.39%
controls:1.34%
—
—
cases:5.73%
controls:1.56%
cases:9.90%
controls:4.72%
cases:14.48%
controls:7.58%
25
214
394
3965
23
188
396
3991
10
56
409
4123
—
24
65
395
4110
40
194
364
3915
54
286
319
3489
codeine and paracetamol
N02AJ06 [1123647]
N02AJ06 [1123647]
2.8e-01
7.9e-01
8.7e-01
—
1.6e+00
5.2e-01
4.9e-01
cases:10.74%
controls:8.33%
cases:6.68%
controls:3.16%
cases:1.19%
controls:0.50%
—
—
cases:2.39%
controls:0.50%
cases:5.94%
controls:3.63%
cases:18.77%
controls:12.42%
45
348
374
3831
28
132
391
4047
5
21
414
4158
—
10
21
409
4154
24
149
380
3960
70
469
303
3306
Granulocytes/Leukocytes in Blood
30395-8 [3035933]
30395-8 [3035933]
—
—
—
—
—
—
2.8e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.68%
controls:0.16%
—
—
—
—
—
—
10
6
363
3769
Diffusion capacity of lung
54715006 [4182985]
54715006 [4182985]
—
—
—
—
—
—
2.8e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.49%
controls:0.21%
—
—
—
—
—
—
13
8
360
3767
Hematology
82 [38004501]
82 [38004501]
6.6e-01
1.0e+00
—
—
1.9e+00
1.5e+00
1.3e+00
cases:1.43%
controls:0.74%
cases:1.91%
controls:0.69%
—
—
—
—
cases:1.43%
controls:0.22%
cases:2.97%
controls:0.68%
cases:4.02%
controls:1.17%
6
31
413
4148
8
29
411
4150
—
—
6
9
413
4166
12
28
392
4081
15
44
358
3731
Paranasal sinuses X-ray examination without contrast
DM1AA [2001301740]
DM1AA [2001301740]
—
—
1.0e+50
—
—
—
2.7e+00
—
—
—
—
cases:1.19%
controls:0.00%
—
—
—
—
—
—
cases:2.41%
controls:0.16%
—
—
5
0
414
4179
—
—
—
9
6
364
3769
Protein [Presence] in Urine by Test strip
20454-5 [3014051]
20454-5 [3014051]
-1.1e-01
3.9e-01
—
—
2.7e+00
-1.4e-01
1.2e-01
cases:1.91%
controls:2.13%
cases:2.39%
controls:1.63%
—
—
—
—
cases:2.15%
controls:0.14%
cases:1.73%
controls:2.00%
cases:5.90%
controls:5.25%
8
89
411
4090
10
68
409
4111
—
—
9
6
410
4169
7
82
397
4027
22
198
351
3577
itraconazole; oral, parenteral
J02AC02 [21603081]
J02AC02 [21603081]
1.0e+00
1.7e+00
—
—
—
—
6.1e-01
cases:3.82%
controls:1.41%
cases:2.15%
controls:0.41%
—
—
—
—
—
—
—
—
cases:2.41%
controls:1.32%
16
59
403
4120
9
17
410
4162
—
—
—
—
9
50
364
3725
CT of paranasal sinuses and face area
DM1AD [2001301741]
DM1AD [2001301741]
—
—
—
—
—
—
2.7e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.68%
controls:0.19%
—
—
—
—
—
—
10
7
363
3768
ciprofloxacin; oral, parenteral
J01MA02 [21603009]
J01MA02 [21603009]
6.7e-01
7.4e-01
2.0e+00
—
—
4.0e-01
2.9e-01
cases:9.79%
controls:5.26%
cases:3.58%
controls:1.75%
cases:1.43%
controls:0.19%
—
—
—
—
cases:2.48%
controls:1.68%
cases:7.77%
controls:5.96%
41
220
378
3959
15
73
404
4106
6
8
413
4171
—
—
10
69
394
4040
29
225
344
3550
IgG subclass 4 [Mass/volume] in Serum
2469-5 [3024980]
2469-5 [3024980]
—
1.0e+50
—
—
1.0e+50
—
2.7e+00
—
—
cases:1.91%
controls:0.00%
—
—
—
—
cases:2.15%
controls:0.00%
—
—
cases:1.88%
controls:0.13%
—
8
0
411
4179
—
—
9
0
410
4175
—
7
5
366
3770
Chronic sinusitis, unspecified
J32.9 [45596278]
J32.9 [45596278]
—
—
—
—
—
—
2.7e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:1.88%
controls:0.13%
—
—
—
—
—
—
7
5
366
3770
Specific gravity of Urine by Refractometry
5810-7 [3019150]
5810-7 [3019150]
-5.7e-02
6.6e-01
2.7e+00
—
—
—
1.5e-01
cases:2.63%
controls:2.78%
cases:2.86%
controls:1.51%
cases:1.67%
controls:0.12%
—
—
—
—
—
—
cases:6.17%
controls:5.35%
11
116
408
4063
12
63
407
4116
7
5
412
4174
—
—
—
23
202
350
3573
Amylase [Enzymatic activity/volume] in Serum or Plasma
1798-8 [3016771]
1798-8 [3016771]
-1.9e-01
1.0e+00
2.7e+00
—
2.0e+00
9.0e-01
4.1e-01
cases:2.39%
controls:2.87%
cases:2.86%
controls:1.05%
cases:1.67%
controls:0.12%
—
—
cases:1.19%
controls:0.17%
cases:3.22%
controls:1.34%
cases:8.31%
controls:5.70%
10
120
409
4059
12
44
407
4135
7
5
412
4174
—
5
7
414
4168
13
55
391
4054
31
215
342
3560
telithromycin; oral
J01FA15 [21602983]
J01FA15 [21602983]
7.9e-01
2.6e+00
—
—
—
-1.0e+50
1.0e+00
cases:2.39%
controls:1.10%
cases:2.63%
controls:0.19%
—
—
—
—
—
—
cases:0.00%
controls:0.19%
cases:1.88%
controls:0.69%
10
46
409
4133
11
8
408
4171
—
—
—
0
8
404
4101
7
26
366
3749
zafirlukast; oral
R03DC01 [21603354]
R03DC01 [21603354]
—
—
—
—
—
—
2.5e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:1.61%
controls:0.13%
—
—
—
—
—
—
6
5
367
3770
Ulcerative colitis, unspecified
K51.9 [45605941]
K51.9 [45605941]
—
—
—
—
—
—
2.5e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:1.61%
controls:0.13%
—
—
—
—
—
—
6
5
367
3770
ambroxol; oral
R05CB06 [21603385]
R05CB06 [21603385]
9.2e-01
1.6e+00
—
—
—
4.4e-01
6.3e-01
cases:4.53%
controls:1.87%
cases:2.86%
controls:0.60%
—
—
—
—
—
—
cases:1.24%
controls:0.80%
cases:4.29%
controls:2.33%
19
78
400
4101
12
25
407
4154
—
—
—
5
33
399
4076
16
88
357
3687
Bone marrow biopsy
XW000 [2001310618]
XW000 [2001310618]
—
2.5e+00
—
—
—
—
—
—
—
cases:1.43%
controls:0.12%
—
—
—
—
—
—
—
—
—
—
—
6
5
413
4174
—
—
—
—
—
Oncology Clinic/Center
261QX0200X [38004268]
261QX0200X [38004268]
2.5e-01
3.6e-01
—
—
2.5e+00
2.8e-01
4.8e-02
cases:5.25%
controls:4.14%
cases:1.91%
controls:1.34%
—
—
—
—
cases:1.43%
controls:0.12%
cases:1.73%
controls:1.31%
cases:4.83%
controls:4.61%
22
173
397
4006
8
56
411
4123
—
—
6
5
413
4170
7
54
397
4055
18
174
355
3601
Blood group antibody screen [Presence] in Serum or Plasma
890-4 [3001079]
890-4 [3001079]
-5.4e-02
5.6e-01
2.5e+00
—
—
5.4e-01
-7.0e-02
cases:3.82%
controls:4.02%
cases:3.10%
controls:1.79%
cases:1.67%
controls:0.14%
—
—
—
—
cases:3.47%
controls:2.04%
cases:5.63%
controls:6.01%
16
168
403
4011
13
75
406
4104
7
6
412
4173
—
—
14
84
390
4025
21
227
352
3548
ciclosporin; oral, parenteral
L04AD01 [21603924]
L04AD01 [21603924]
—
—
—
—
—
—
2.5e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.14%
controls:0.19%
—
—
—
—
—
—
8
7
365
3768
alendronic acid and colecalciferol; oral
M05BB03 [21604160]
M05BB03 [21604160]
—
—
—
—
—
—
2.5e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.14%
controls:0.19%
—
—
—
—
—
—
8
7
365
3768
Standard cardiac ultrasound examination
FM1AE [2001303278]
FM1AE [2001303278]
7.0e-01
8.1e-01
—
1.0e+50
—
1.7e+00
8.0e-01
cases:3.58%
controls:1.82%
cases:2.39%
controls:1.08%
—
—
cases:1.43%
controls:0.00%
—
—
cases:3.96%
controls:0.78%
cases:6.17%
controls:2.86%
15
76
404
4103
10
45
409
4134
—
6
0
413
4179
—
16
32
388
4077
23
108
350
3667
General anesthesia, balanced
WX408 [2001310808]
WX408 [2001310808]
4.4e-01
1.5e+00
—
—
—
—
9.9e-01
cases:3.82%
controls:2.49%
cases:2.63%
controls:0.62%
—
—
—
—
—
—
—
—
cases:5.09%
controls:1.96%
16
104
403
4075
11
26
408
4153
—
—
—
—
19
74
354
3701
Observation for suspected disease or condition, unspecified
Z03.9 [45552062]
Z03.9 [45552062]
3.4e-01
1.1e+00
—
—
—
2.4e+00
5.9e-01
cases:1.91%
controls:1.36%
cases:1.91%
controls:0.65%
—
—
—
—
—
—
cases:4.21%
controls:0.39%
cases:3.75%
controls:2.12%
8
57
411
4122
8
27
411
4152
—
—
—
17
16
387
4093
14
80
359
3695
Esophagoscopy, gastroscopy and duodenoscopy
UJD10 [2001304788]
UJD10 [2001304788]
4.2e-01
9.8e-01
—
—
—
1.4e+00
9.6e-01
cases:4.53%
controls:3.02%
cases:2.63%
controls:1.01%
—
—
—
—
—
—
cases:3.96%
controls:1.00%
cases:8.85%
controls:3.58%
19
126
400
4053
11
42
408
4137
—
—
—
16
41
388
4068
33
135
340
3640
Connective tissue diseases, rheumatoid arthritis and comparable disease
202 [2001600200]
202 [2001600200]
—
-1.0e+50
—
—
—
2.3e+00
1.5e+00
—
—
cases:0.00%
controls:0.12%
—
—
—
—
—
—
cases:2.48%
controls:0.24%
cases:2.14%
controls:0.50%
—
0
5
419
4174
—
—
—
10
10
394
4099
8
19
365
3756
Neutrophil cytoplasmic Ab.perinuclear [Titer] in Serum by Immunofluorescence
14278-6 [3003284]
14278-6 [3003284]
—
2.0e+00
1.0e+50
—
1.0e+50
—
2.3e+00
—
—
cases:1.19%
controls:0.17%
cases:1.19%
controls:0.00%
—
—
cases:2.63%
controls:0.00%
—
—
cases:2.68%
controls:0.26%
—
5
7
414
4172
5
0
414
4179
—
11
0
408
4175
—
10
10
363
3765
Influenza virus A and B and SARS-CoV-2 (COVID-19) and Respiratory syncytial virus RNA panel - Respiratory system specimen by NAA with probe detection
95941-1 [36031861]
95941-1 [36031861]
—
2.3e+00
—
—
—
2.3e+00
4.6e-01
—
—
cases:1.19%
controls:0.12%
—
—
—
—
—
—
cases:1.49%
controls:0.15%
cases:1.34%
controls:0.85%
—
5
5
414
4174
—
—
—
6
6
398
4103
5
32
368
3743
salbutamol and ipratropium bromide
R03AL02 [43534844]
R03AL02 [43534844]
—
—
—
—
—
—
2.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:1.88%
controls:0.19%
—
—
—
—
—
—
7
7
366
3768
Chronic mucoid otitis media
H65.3 [45567124]
H65.3 [45567124]
—
—
—
—
—
—
2.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:1.61%
controls:0.16%
—
—
—
—
—
—
6
6
367
3769
Buprenorphine [Presence] in Urine by Screen method
93494-3 [1001926]
93494-3 [1001926]
—
—
—
—
—
—
2.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:1.34%
controls:0.13%
—
—
—
—
—
—
5
5
368
3770
warfarin; oral, parenteral
B01AA03 [21600965]
B01AA03 [21600965]
2.4e-01
6.2e-01
8.6e-01
—
1.4e+00
9.1e-01
5.7e-01
cases:5.97%
controls:4.76%
cases:6.44%
controls:3.59%
cases:1.91%
controls:0.81%
—
—
cases:3.82%
controls:0.96%
cases:8.42%
controls:3.58%
cases:9.12%
controls:5.35%
25
199
394
3980
27
150
392
4029
8
34
411
4145
—
16
40
403
4135
34
147
370
3962
34
202
339
3573
Hemoglobin [Presence] in Urine by Test strip
5794-3 [3011397]
5794-3 [3011397]
-4.2e-01
7.4e-01
2.3e+00
—
—
4.7e-02
5.8e-02
cases:1.67%
controls:2.51%
cases:2.63%
controls:1.27%
cases:1.67%
controls:0.17%
—
—
—
—
cases:1.73%
controls:1.65%
cases:5.09%
controls:4.82%
7
105
412
4074
11
53
408
4126
7
7
412
4172
—
—
7
68
397
4041
19
182
354
3593
Wheezing
R06.2 [45548946]
R06.2 [45548946]
1.5e+00
2.3e+00
—
—
—
—
—
cases:1.19%
controls:0.26%
cases:1.43%
controls:0.14%
—
—
—
—
—
—
—
—
—
—
5
11
414
4168
6
6
413
4173
—
—
—
—
—
Lysozyme [Mass/volume] in Serum or Plasma
2589-0 [3012110]
2589-0 [3012110]
1.6e+00
2.3e+00
—
—
1.0e+50
—
—
cases:1.19%
controls:0.24%
cases:1.43%
controls:0.14%
—
—
—
—
cases:1.19%
controls:0.00%
—
—
—
—
5
10
414
4169
6
6
413
4173
—
—
5
0
414
4175
—
—
Neutrophil cytoplasmic Ab.classic [Titer] in Serum by Immunofluorescence
14277-8 [3004383]
14277-8 [3004383]
—
2.0e+00
1.0e+50
—
1.0e+50
—
2.2e+00
—
—
cases:1.19%
controls:0.17%
cases:1.19%
controls:0.00%
—
—
cases:2.63%
controls:0.00%
—
—
cases:2.68%
controls:0.29%
—
5
7
414
4172
5
0
414
4179
—
11
0
408
4175
—
10
11
363
3764
Fungus identified in Specimen by Culture
580-1 [3000494]
580-1 [3000494]
4.7e-01
2.2e+00
1.0e+50
—
—
1.5e+00
9.7e-01
cases:1.67%
controls:1.05%
cases:2.63%
controls:0.29%
cases:2.15%
controls:0.00%
—
—
—
—
cases:1.98%
controls:0.44%
cases:3.75%
controls:1.46%
7
44
412
4135
11
12
408
4167
9
0
410
4179
—
—
8
18
396
4091
14
55
359
3720
More than one and less than three hours
ZXE10 [2001311401]
ZXE10 [2001311401]
8.5e-02
4.1e-01
—
—
—
1.1e+00
1.1e+00
cases:4.77%
controls:4.40%
cases:1.43%
controls:0.96%
—
—
—
—
—
—
cases:3.71%
controls:1.24%
cases:11.53%
controls:4.13%
20
184
399
3995
6
40
413
4139
—
—
—
15
51
389
4058
43
156
330
3619
Scheduled procedure
ZXD10 [2001311387]
ZXD10 [2001311387]
5.8e-01
8.6e-01
-1.0e+50
—
—
1.3e+00
9.3e-01
cases:8.59%
controls:4.98%
cases:3.10%
controls:1.34%
cases:0.00%
controls:0.14%
—
—
—
—
cases:4.95%
controls:1.41%
cases:12.33%
controls:5.27%
36
208
383
3971
13
56
406
4123
0
6
419
4173
—
—
20
58
384
4051
46
199
327
3576
desloratadine; oral
R06AX27 [21603526]
R06AX27 [21603526]
1.1e+00
1.2e+00
—
—
1.1e+00
8.9e-01
3.8e-01
cases:7.64%
controls:2.78%
cases:4.77%
controls:1.56%
—
—
—
—
cases:1.19%
controls:0.41%
cases:3.71%
controls:1.56%
cases:6.17%
controls:4.29%
32
116
387
4063
20
65
399
4114
—
—
5
17
414
4158
15
64
389
4045
23
162
350
3613
Protein.monoclonal band 1 [Mass/volume] in Serum or Plasma by Electrophoresis
51435-6 [3029713]
51435-6 [3029713]
—
—
—
—
—
2.2e+00
—
—
—
—
—
—
—
—
—
—
—
cases:1.49%
controls:0.17%
—
—
—
—
—
—
—
6
7
398
4102
—
Pulmonary embolism without mention of acute cor pulmonale
I26.9 [45552785]
I26.9 [45552785]
—
—
—
—
—
2.2e+00
1.2e+00
—
—
—
—
—
—
—
—
—
—
cases:1.49%
controls:0.17%
cases:1.61%
controls:0.50%
—
—
—
—
—
6
7
398
4102
6
19
367
3756
Prick test
37968009 [4242723]
37968009 [4242723]
2.1e+00
—
—
—
—
—
8.9e-01
cases:2.39%
controls:0.29%
—
—
—
—
—
—
—
—
—
—
cases:1.34%
controls:0.56%
10
12
409
4167
—
—
—
—
—
5
21
368
3754
Bacteria identified in Sputum by Culture
6460-0 [3023419]
6460-0 [3023419]
—
—
—
—
—
—
2.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.41%
controls:0.29%
—
—
—
—
—
—
9
11
364
3764
One hour or less
ZXE00 [2001311394]
ZXE00 [2001311394]
3.7e-01
6.0e-01
-1.0e+50
—
—
1.2e+00
9.7e-01
cases:5.73%
controls:4.04%
cases:2.63%
controls:1.46%
cases:0.00%
controls:0.12%
—
—
—
—
cases:3.47%
controls:1.12%
cases:11.26%
controls:4.58%
24
169
395
4010
11
61
408
4118
0
5
419
4174
—
—
14
46
390
4063
42
173
331
3602
Gas panel - Arterial blood
24336-0 [3019060]
24336-0 [3019060]
—
2.1e+00
—
—
—
—
1.9e-01
—
—
cases:1.91%
controls:0.24%
—
—
—
—
—
—
—
—
cases:1.34%
controls:1.11%
—
8
10
411
4169
—
—
—
—
5
42
368
3733
Extensive structural and functional ultrasound examination of heart
FM1EE [2001303307]
FM1EE [2001303307]
5.6e-01
9.1e-01
—
—
—
1.2e+00
8.5e-01
cases:3.58%
controls:2.08%
cases:2.86%
controls:1.17%
—
—
—
—
—
—
cases:3.22%
controls:1.00%
cases:6.70%
controls:2.97%
15
87
404
4092
12
49
407
4130
—
—
—
13
41
391
4068
25
112
348
3663
Gastro-oesophageal reflux disease without oesophagitis
K21.9 [45538509]
K21.9 [45538509]
—
—
—
—
—
2.0e+00
5.3e-01
—
—
—
—
—
—
—
—
—
—
cases:1.49%
controls:0.19%
cases:1.61%
controls:0.95%
—
—
—
—
—
6
8
398
4101
6
36
367
3739
Doppler ultrasound examination of heart
FM1DE [2001303299]
FM1DE [2001303299]
—
—
—
—
—
2.0e+00
6.3e-01
—
—
—
—
—
—
—
—
—
—
cases:1.49%
controls:0.19%
cases:1.88%
controls:1.01%
—
—
—
—
—
6
8
398
4101
7
38
366
3737
Bicarbonate [Moles/volume] in Arterial blood
1960-4 [3008152]
1960-4 [3008152]
—
2.0e+00
—
—
—
—
—
—
—
cases:2.15%
controls:0.29%
—
—
—
—
—
—
—
—
—
—
—
9
12
410
4167
—
—
—
—
—
Hand and fingers X-ray examination
ND2AA [2001307607]
ND2AA [2001307607]
—
-1.0e+50
—
—
—
—
2.0e+00
—
—
cases:0.00%
controls:0.22%
—
—
—
—
—
—
—
—
cases:3.49%
controls:0.48%
—
0
9
419
4170
—
—
—
—
13
18
360
3757
Stomach Pathology biopsy report
66114-0 [40768797]
66114-0 [40768797]
7.3e-01
—
—
—
—
2.0e+00
2.6e-01
cases:1.91%
controls:0.93%
—
—
—
—
—
—
—
—
cases:1.98%
controls:0.27%
cases:1.88%
controls:1.46%
8
39
411
4140
—
—
—
—
8
11
396
4098
7
55
366
3720
Asthma
R96 [2002000961]
R96 [2002000961]
1.2e+00
2.0e+00
—
—
—
—
8.7e-01
cases:2.39%
controls:0.74%
cases:1.91%
controls:0.26%
—
—
—
—
—
—
—
—
cases:2.68%
controls:1.14%
10
31
409
4148
8
11
411
4168
—
—
—
—
10
43
363
3732
Observation for other suspected diseases and conditions
Z03.89 [2000503757]
Z03.89 [2000503757]
2.2e-01
2.0e+00
—
—
—
—
1.0e+00
cases:1.19%
controls:0.96%
cases:1.91%
controls:0.26%
—
—
—
—
—
—
—
—
cases:3.49%
controls:1.30%
5
40
414
4139
8
11
411
4168
—
—
—
—
13
49
360
3726
aPTT in Platelet poor plasma by Coagulation assay
14979-9 [3018677]
14979-9 [3018677]
3.0e-01
1.5e+00
—
—
—
2.0e+00
7.8e-02
cases:1.67%
controls:1.24%
cases:1.67%
controls:0.38%
—
—
—
—
—
—
cases:2.97%
controls:0.41%
cases:2.14%
controls:1.99%
7
52
412
4127
7
16
412
4163
—
—
—
12
17
392
4092
8
75
365
3700
Noninfective gastroenteritis and colitis, unspecified
K52.9 [45572215]
K52.9 [45572215]
—
—
—
—
—
—
2.0e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:1.88%
controls:0.26%
—
—
—
—
—
—
7
10
366
3765
Psychologist
Z2445 [2001311558]
Z2445 [2001311558]
—
—
—
—
—
—
2.0e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:1.88%
controls:0.26%
—
—
—
—
—
—
7
10
366
3765
Telephone, letter or other consultation without direct patient contact
ZY020 [2001311600]
ZY020 [2001311600]
—
—
—
—
—
1.8e+00
2.0e+00
—
—
—
—
—
—
—
—
—
—
cases:1.49%
controls:0.24%
cases:2.95%
controls:0.42%
—
—
—
—
—
6
10
398
4099
11
16
362
3759
IgA [Mass/volume] in Serum or Plasma
2458-8 [3007164]
2458-8 [3007164]
6.6e-01
1.2e+00
—
—
—
1.9e+00
6.6e-01
cases:2.86%
controls:1.51%
cases:2.15%
controls:0.67%
—
—
—
—
—
—
cases:2.48%
controls:0.37%
cases:4.56%
controls:2.41%
12
63
407
4116
9
28
410
4151
—
—
—
10
15
394
4094
17
91
356
3684
Influenza virus B RNA [Presence] in Specimen by NAA with probe detection
40982-1 [3038288]
40982-1 [3038288]
—
1.9e+00
—
1.0e+50
—
1.3e+00
3.5e-01
—
—
cases:3.34%
controls:0.50%
—
—
cases:1.67%
controls:0.00%
—
—
cases:1.49%
controls:0.41%
cases:2.68%
controls:1.91%
—
14
21
405
4158
—
7
0
412
4179
—
6
17
398
4092
10
72
363
3703
12 lead EKG panel
34534-8 [3044889]
34534-8 [3044889]
-3.1e-01
4.3e-01
1.9e+00
—
9.6e-01
3.2e-01
2.0e-01
cases:7.16%
controls:9.50%
cases:7.88%
controls:5.26%
cases:4.53%
controls:0.69%
—
—
cases:1.91%
controls:0.74%
cases:6.93%
controls:5.11%
cases:17.96%
controls:15.18%
30
397
389
3782
33
220
386
3959
19
29
400
4150
—
8
31
411
4144
28
210
376
3899
67
573
306
3202
Oxygen saturation in Arterial blood
2708-6 [3016502]
2708-6 [3016502]
—
1.9e+00
—
—
—
—
-1.3e-01
—
—
cases:2.39%
controls:0.36%
—
—
—
—
—
—
—
—
cases:1.61%
controls:1.83%
—
10
15
409
4164
—
—
—
—
6
69
367
3706
Neutrophils [#/volume] in Blood
26499-4 [3017732]
26499-4 [3017732]
1.1e+00
1.9e+00
—
—
—
—
1.2e-01
cases:1.19%
controls:0.41%
cases:1.91%
controls:0.29%
—
—
—
—
—
—
—
—
cases:2.14%
controls:1.91%
5
17
414
4162
8
12
411
4167
—
—
—
—
8
72
365
3703
Protein electrophoresis panel - Serum or Plasma
24351-9 [3004588]
24351-9 [3004588]
1.0e+00
8.7e-01
—
—
—
1.9e+00
—
cases:1.67%
controls:0.62%
cases:1.19%
controls:0.50%
—
—
—
—
—
—
cases:1.73%
controls:0.27%
—
—
7
26
412
4153
5
21
414
4158
—
—
—
7
11
397
4098
—
famotidine; oral, parenteral
A02BA03 [21600084]
A02BA03 [21600084]
—
—
—
—
—
—
1.9e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:1.88%
controls:0.29%
—
—
—
—
—
—
7
11
366
3764
Band form neutrophils/Leukocytes in Blood
26508-2 [3004809]
26508-2 [3004809]
—
—
—
—
—
—
1.9e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:1.88%
controls:0.29%
—
—
—
—
—
—
7
11
366
3764
Respiratory syncytial virus RNA [Identifier] in Specimen by NAA with probe detection
40987-0 [3043924]
40987-0 [3043924]
—
1.8e+00
—
1.0e+50
—
1.3e+00
1.7e-01
—
—
cases:3.10%
controls:0.50%
—
—
cases:1.91%
controls:0.00%
—
—
cases:1.49%
controls:0.39%
cases:2.41%
controls:2.04%
—
13
21
406
4158
—
8
0
411
4179
—
6
16
398
4093
9
77
364
3698
Lactate [Moles/volume] in Serum or Plasma
2524-7 [3014111]
2524-7 [3014111]
-1.0e+50
1.8e+00
—
—
—
—
1.6e-01
cases:0.00%
controls:0.67%
cases:1.91%
controls:0.31%
—
—
—
—
—
—
—
—
cases:1.61%
controls:1.38%
0
28
419
4151
8
13
411
4166
—
—
—
—
6
52
367
3723
Arthrocentesis, unspecified region, unspecified region
TNX10 [2001308560]
TNX10 [2001308560]
—
—
—
—
—
—
1.8e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.41%
controls:0.40%
—
—
—
—
—
—
9
15
364
3760
Base excess in Arterial blood by calculation
1925-7 [3003396]
1925-7 [3003396]
—
1.8e+00
—
—
—
—
-3.3e-01
—
—
cases:2.86%
controls:0.48%
—
—
—
—
—
—
—
—
cases:1.34%
controls:1.85%
—
12
20
407
4159
—
—
—
—
5
70
368
3705
pH of Arterial blood
2744-1 [3019977]
2744-1 [3019977]
—
1.8e+00
—
—
—
—
-1.6e-01
—
—
cases:2.86%
controls:0.48%
—
—
—
—
—
—
—
—
cases:1.61%
controls:1.88%
—
12
20
407
4159
—
—
—
—
6
71
367
3704
formoterol and budesonide
R03AK07 [21603281]
R03AK07 [21603281]
9.3e-01
1.8e+00
—
—
—
1.2e+00
8.7e-01
cases:2.15%
controls:0.86%
cases:2.39%
controls:0.41%
—
—
—
—
—
—
cases:1.98%
controls:0.61%
cases:3.22%
controls:1.38%
9
36
410
4143
10
17
409
4162
—
—
—
8
25
396
4084
12
52
361
3723
Foot and toes X-ray examination
NH3AA [2001308267]
NH3AA [2001308267]
—
—
—
—
—
—
1.8e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.22%
controls:0.56%
—
—
—
—
—
—
12
21
361
3754
Cyclic citrullinated peptide Ab [Units/volume] in Serum
53027-9 [3041942]
53027-9 [3041942]
3.8e-01
1.8e+00
1.0e+50
—
—
1.5e+00
8.9e-01
cases:1.67%
controls:1.15%
cases:2.63%
controls:0.45%
cases:1.19%
controls:0.00%
—
—
—
—
cases:1.49%
controls:0.34%
cases:4.02%
controls:1.70%
7
48
412
4131
11
19
408
4160
5
0
414
4179
—
—
6
14
398
4095
15
64
358
3711
EKG study
11524-6 [3013512]
11524-6 [3013512]
5.8e-02
1.4e-01
1.8e+00
—
—
-8.0e-02
-5.6e-02
cases:3.34%
controls:3.16%
cases:2.63%
controls:2.30%
cases:1.67%
controls:0.29%
—
—
—
—
cases:2.23%
controls:2.41%
cases:6.43%
controls:6.78%
14
132
405
4047
11
96
408
4083
7
12
412
4167
—
—
9
99
395
4010
24
256
349
3519
cefuroxime; oral, parenteral
J01DC02 [21602884]
J01DC02 [21602884]
4.5e-01
1.8e+00
—
—
—
—
8.5e-01
cases:1.91%
controls:1.22%
cases:1.67%
controls:0.29%
—
—
—
—
—
—
—
—
cases:2.14%
controls:0.93%
8
51
411
4128
7
12
412
4167
—
—
—
—
8
35
365
3740
Oxygen [Partial pressure] in Arterial blood
2703-7 [3027801]
2703-7 [3027801]
—
1.8e+00
—
—
—
—
-1.6e-01
—
—
cases:2.86%
controls:0.50%
—
—
—
—
—
—
—
—
cases:1.61%
controls:1.88%
—
12
21
407
4158
—
—
—
—
6
71
367
3704
Carbon dioxide [Partial pressure] in Arterial blood
2019-8 [3027946]
2019-8 [3027946]
—
1.8e+00
—
—
—
—
-1.6e-01
—
—
cases:2.86%
controls:0.50%
—
—
—
—
—
—
—
—
cases:1.61%
controls:1.88%
—
12
21
407
4158
—
—
—
—
6
71
367
3704
formoterol, glycopyrronium bromide and budesonide
R03AL11 [715850]
R03AL11 [715850]
1.0e+00
1.8e+00
—
—
—
9.8e-01
9.7e-02
cases:2.15%
controls:0.77%
cases:1.91%
controls:0.34%
—
—
—
—
—
—
cases:1.49%
controls:0.56%
cases:1.34%
controls:1.22%
9
32
410
4147
8
14
411
4165
—
—
—
6
23
398
4086
5
46
368
3729
Initiation, adjustment, discontinuation or repetition of medication
SPAT1253 [2001700354]
SPAT1253 [2001700354]
2.8e-01
3.6e-01
—
—
1.8e+00
1.4e-01
1.6e-01
cases:4.77%
controls:3.66%
cases:2.39%
controls:1.68%
—
—
—
—
cases:1.91%
controls:0.34%
cases:1.98%
controls:1.73%
cases:6.43%
controls:5.51%
20
153
399
4026
10
70
409
4109
—
—
8
14
411
4161
8
71
396
4038
24
208
349
3567
Rheumatoid factor [Units/volume] in Serum or Plasma
11572-5 [3021614]
11572-5 [3021614]
-6.8e-02
1.7e+00
1.0e+50
—
—
1.4e+00
8.1e-01
cases:1.43%
controls:1.53%
cases:2.15%
controls:0.38%
cases:1.43%
controls:0.00%
—
—
—
—
cases:1.49%
controls:0.37%
cases:4.29%
controls:1.96%
6
64
413
4115
9
16
410
4163
6
0
413
4179
—
—
6
15
398
4094
16
74
357
3701
Thorax X-ray examination outside radiological department
GD1UA [2001303652]
GD1UA [2001303652]
7.2e-01
—
—
—
-1.0e+50
1.7e+00
9.2e-01
cases:2.39%
controls:1.17%
—
—
—
—
—
—
cases:0.00%
controls:0.12%
cases:2.48%
controls:0.46%
cases:4.02%
controls:1.64%
10
49
409
4130
—
—
—
0
5
419
4170
10
19
394
4090
15
62
358
3713
Hemoglobin [Mass/volume] in Arterial blood
30313-1 [3002173]
30313-1 [3002173]
—
1.7e+00
—
—
—
—
-2.7e-01
—
—
cases:1.91%
controls:0.36%
—
—
—
—
—
—
—
—
cases:1.34%
controls:1.75%
—
8
15
411
4164
—
—
—
—
5
66
368
3709
Anaemia, unspecified
D64.9 [45600610]
D64.9 [45600610]
1.6e+00
1.3e+00
—
—
—
1.9e+00
4.6e-01
cases:2.63%
controls:0.53%
cases:1.19%
controls:0.34%
—
—
—
—
—
—
cases:1.49%
controls:0.22%
cases:1.34%
controls:0.85%
11
22
408
4157
5
14
414
4165
—
—
—
6
9
398
4100
5
32
368
3743
LabWAS
↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
142
240
8.21
86.42
2.7
1.3
357.47
292.35
u/ml
0.26
135
222
51
25
22.90
68.07
1.9
1.2
4.41
0.13
u/ml
1.18
39
11
90
132
8.28
60.88
2.8
2.9
—
—
—
0
0
70
85
9.58
55.03
1.5
1.3
—
—
—
0
0
60
64
10.67
51.84
1.5
1.3
251.43
116.67
titre
—
7
6
40
34
12.82
39.94
1.2
1.1
—
—
—
0
0
345
2052
3.99
35.47
15.7
5.9
0.33
0.19
e9/l
18.00
329
1782
35
30
12.57
34.68
1.9
1.6
—
—
—
0
0
345
2198
3.50
28.63
16.6
9.5
4.92
4.06
e9/l
5.80
325
1907
36
43
9.02
28.26
4.1
4.1
—
—
—
0
0
51
93
6.06
27.45
1.7
1.5
—
—
—
0
0
53
103
5.70
26.68
2.0
1.6
—
—
—
0
0
42
70
6.52
24.67
2.1
1.8
—
—
—
0
0
45
84
5.84
23.58
1.7
1.5
—
—
—
0
0
93
310
3.53
23.27
2.6
1.4
—
—
—
0
0
51
110
5.10
22.80
2.0
1.6
—
—
—
0
0
45
89
5.51
22.15
1.1
1.2
—
—
—
0
0
34
51
7.13
21.99
1.7
1.6
—
—
—
0
0
57
153
4.12
19.36
1.7
1.7
14.39
8.67
iu/ml
—
9
40
100
390
3.01
19.05
2.6
2.0
311.11
382.68
nmol/l
0.96
95
357
35
66
5.67
18.08
1.8
1.6
—
—
—
0
0
25
34
7.73
17.55
2.3
1.9
—
—
—
0
0
263
1713
2.30
16.29
19.0
11.7
0.00
0.00
e9/l
0.17
233
1399
37
81
4.89
16.18
1.8
1.6
—
—
—
0
0
25
38
6.91
15.91
2.3
1.8
—
—
—
0
0
26
46
5.94
14.30
1.1
1.2
—
—
—
0
0
140
734
2.32
14.18
2.6
1.9
—
—
—
0
0
115
560
2.42
13.73
2.3
1.8
—
—
—
0
0
41
111
3.97
13.69
1.1
1.1
—
1.60
—
0
5
259
1756
2.13
13.52
3.3
2.5
82.76
79.09
nmol/l
1.15
246
1558
110
529
2.43
13.48
2.4
1.9
—
—
—
0
0
28
57
5.17
13.28
1.7
1.6
—
—
—
0
0
364
2856
2.48
12.82
9.7
4.4
14.49
12.56
mm/h
1.79
358
2654
41
117
3.76
12.71
1.9
1.5
—
—
—
0
0
44
133
3.56
12.54
1.3
1.2
0.35
0.19
u/ml
—
6
10
20
14
14.89
12.38
1.6
1.1
—
—
—
0
0
29
66
4.63
12.09
10.9
6.0
172.80
152.43
iu/ml
—
5
7
33
86
4.06
11.59
1.2
1.3
—
—
—
0
0
296
2193
2.04
11.19
7.3
6.4
10.53
11.39
umol/l
1.25
289
2087
282
2077
1.97
10.55
9.6
6.8
1.21
1.21
mmol/l
0.14
258
1802
34
98
3.67
10.38
1.9
2.1
124.63
127.36
g/l
0.22
24
81
261
1881
1.93
10.33
8.0
6.2
1.21
1.21
mmol/l
0.01
252
1720
36
113
3.38
9.68
1.6
1.5
1.28
0.01
iu/ml
—
8
15
16
14
11.80
9.13
3.5
1.4
39.25
71.74
ug/l
1.27
16
14
22
52
4.40
8.76
1.2
1.1
0.47
1.19
u/ml
0.92
13
26
66
304
2.37
8.68
1.7
1.6
—
—
—
0
0
361
2986
2.09
8.66
13.0
8.2
76.72
80.60
u/l
1.24
351
2819
27
78
3.62
8.22
1.3
1.4
—
—
—
0
0
27
78
3.62
8.22
1.3
1.4
—
—
—
0
0
18
38
4.89
8.18
1.9
1.5
—
—
—
0
0
18
38
4.89
8.18
1.9
1.5
—
—
—
0
0
18
38
4.89
8.18
1.9
1.5
—
—
—
0
0
53
232
2.46
7.78
4.1
2.6
1.91
1.94
mmol/l
0.02
42
168
68
334
2.22
7.68
3.4
3.3
224.71
216.92
ng/l
0.04
62
308
119
718
1.90
7.66
3.3
2.4
13.15
12.54
umol/l
0.30
112
662
161
1072
1.78
7.52
2.9
2.2
2.88
3.01
mg/l
0.31
143
920
139
892
1.81
7.31
2.0
1.6
1.38
1.29
mg/l
0.13
113
717
93
526
1.97
7.22
7.8
5.0
1.03
1.03
mmol/l
0.05
88
480
167
1139
1.74
7.09
4.2
3.3
0.30
0.43
e6/l
0.58
133
833
108
647
1.88
7.05
1.4
1.3
10.50
11.41
u/ml
0.06
36
253
297
2374
1.75
7.05
6.2
5.0
6.69
6.72
mmol/l
0.10
288
2261
131
835
1.80
7.01
4.6
4.2
186.92
298.09
ng/l
0.58
110
689
110
665
1.87
6.97
3.2
2.4
2.27
2.28
g/l
0.10
104
610
188
1336
1.70
6.82
4.3
3.5
145.31
113.89
e6/l
0.12
156
1031
88
498
1.96
6.80
6.5
7.8
1.55
1.02
mmol/l
0.51
75
423
11
9
12.49
6.61
1.9
1.9
—
—
—
0
0
11
9
12.49
6.61
1.9
1.9
—
—
—
0
0
140
929
1.74
6.44
3.2
2.7
4.06
5.11
e6/l
0.62
132
857
103
625
1.84
6.41
3.3
2.3
23.14
21.92
%
0.38
97
583
11
10
11.24
6.33
2.0
1.8
—
—
—
0
0
260
2042
1.65
6.23
3.3
2.7
—
—
—
0
0
113
712
1.79
6.19
1.5
1.3
22.80
32.77
iu/ml
0.74
35
227
20
58
3.56
6.08
1.3
1.4
—
—
—
0
0
12
15
8.19
5.87
1.8
1.9
—
—
—
0
0
180
1307
1.63
5.77
4.0
3.3
28.62
32.12
u/l
1.55
172
1234
16
41
4.01
5.76
1.2
1.0
0.29
0.35
u/ml
0.09
11
20
235
1825
1.61
5.69
7.4
4.7
33.83
35.38
g/l
4.07
227
1712
16
32
5.15
5.61
1.1
1.0
0.79
0.92
u/ml
0.09
11
11
59
310
2.04
5.58
4.0
3.5
88.05
81.91
ng/l
0.23
50
270
8
5
16.24
5.43
1.4
1.4
—
—
—
0
0
186
1383
1.59
5.29
4.7
3.3
1525.27
1387.38
ng/l
0.21
173
1190
5
0
+∞
5.22
1.6
0.0
1.03
—
mg/l
—
5
0
5
0
+∞
5.22
1.6
0.0
4.73
—
mg/l
—
5
0
5
0
+∞
5.22
1.6
0.0
1.90
—
mg/l
—
5
0
5
0
+∞
5.22
1.6
0.0
4.26
—
mg/l
—
5
0
223
1735
1.57
5.19
3.8
2.9
124.79
130.68
ug/l
0.17
205
1601
11
15
7.49
5.17
3.1
6.1
—
—
—
0
0
13
23
5.79
5.10
1.5
1.6
—
—
—
0
0
11
16
7.02
4.98
1.9
1.6
—
—
—
0
0
11
16
7.02
4.98
1.9
1.6
—
—
—
0
0
11
16
7.02
4.98
1.9
1.6
—
—
—
0
0
11
16
7.02
4.98
1.9
1.6
—
—
—
0
0
13
24
5.55
4.95
1.5
1.6
—
—
—
0
0
100
648
1.70
4.87
3.6
3.2
0.73
2.24
e6/l
3.24
55
309
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
28
115
2.53
4.73
2.9
2.3
0.30
0.37
iu/ml
0.78
20
66
189
1439
1.54
4.71
4.9
3.4
2.34
2.35
mmol/l
1.31
179
1302
13
28
4.75
4.40
1.5
1.6
—
—
—
0
0
15
45
3.41
4.36
1.1
1.1
—
—
—
0
0
103
694
1.63
4.28
3.4
3.0
0.46
1.12
e6/l
2.69
58
355
14
34
4.22
4.24
1.1
1.1
—
—
—
0
0
100
675
1.62
4.11
5.0
3.2
0.82
0.81
mmol/l
0.20
95
634
13
34
3.91
3.72
1.2
1.1
—
—
—
0
0
13
34
3.91
3.72
1.6
1.7
—
—
—
0
0
167
1290
1.47
3.66
2.7
2.1
137.36
220.40
u/l
1.91
162
1224
240
1987
1.45
3.65
19.4
14.7
1.28
1.26
inr
0.21
213
1662
48
274
1.84
3.59
1.9
1.7
—
—
—
0
0
7
9
7.88
3.57
1.1
1.6
—
—
—
0
0
11
27
4.15
3.41
1.1
1.1
—
—
—
0
0
12
32
3.82
3.41
1.0
1.0
—
—
—
0
0
12
32
3.82
3.41
1.1
1.1
—
—
—
0
0
36
191
1.96
3.35
1.6
1.8
1.66
1.44
g/l
0.54
30
170
14
48
2.98
3.33
1.2
1.1
2.14
4.11
u/ml
—
7
19
11
28
4.00
3.31
1.1
1.2
—
—
—
0
0
65
416
1.66
3.28
5.6
3.1
3.12
2.14
mmol/l
0.93
58
355
6
7
8.67
3.27
1.2
1.0
0.56
0.18
u/ml
—
6
7
16
60
2.73
3.26
1.1
1.3
—
—
—
0
0
9
19
4.81
3.25
1.4
3.0
521.11
742.95
u/ml
—
9
19
11
29
3.86
3.20
1.1
1.1
—
—
—
0
0
11
29
3.86
3.20
1.1
1.1
—
—
—
0
0
12
35
3.49
3.13
1.8
1.2
—
—
—
0
0
12
35
3.49
3.13
1.8
1.2
—
—
—
0
0
295
2579
1.42
3.08
6.3
4.9
1968.20
1266.96
e6/l
—
5
48
8
16
5.07
3.06
1.0
1.2
—
—
—
0
0
30
155
2.00
3.02
2.6
2.0
149.67
304.28
ug/l
1.58
30
147
61
393
1.64
3.01
2.8
2.3
0.21
0.21
g/l
0.17
56
363
159
1256
1.41
2.97
1.7
1.7
21.10
20.79
nmol/l
0.10
139
1039
21
96
2.25
2.88
1.2
1.2
—
—
—
0
0
133
1034
1.41
2.68
4.1
2.7
352.02
348.76
umol/l
0.13
123
904
5
7
7.21
2.55
1.4
1.7
—
—
—
0
0
29
160
1.87
2.46
2.4
1.8
—
—
—
0
0
391
3663
1.54
2.38
33.2
17.0
23.37
25.20
mg/l
0.60
373
3060
7
17
4.17
2.37
1.0
1.1
—
—
—
0
0
111
858
1.39
2.28
1.5
1.3
0.56
1.40
u/ml
2.06
25
231
5
9
5.60
2.22
2.0
1.6
0.69
0.62
mmol/l
—
5
9
242
2113
1.32
2.19
5.2
4.1
0.00
0.01
estimate
0.50
57
420
6
14
4.33
2.15
1.0
1.1
—
—
—
0
0
238
2079
1.31
2.12
5.1
4.1
0.00
0.00
estimate
-0.00
58
440
240
2103
1.30
2.07
5.2
4.1
0.00
7.70
estimate
0.80
60
455
13
56
2.36
2.06
2.8
2.1
31.00
32.75
pg
0.69
13
56
9
34
2.68
1.87
1.1
1.2
101.67
105.62
pmol/l
—
9
34
156
1305
1.30
1.86
2.9
2.6
57.64
65.30
u/l
0.61
151
1210
210
1826
1.28
1.86
2.4
2.2
96.98
96.35
pmol/l
0.07
108
921
21
116
1.85
1.82
2.3
1.5
—
—
—
0
0
18
95
1.93
1.78
2.6
1.5
—
—
—
0
0
21
117
1.83
1.77
1.3
1.1
—
—
—
0
0
9
36
2.53
1.75
1.0
1.3
—
—
—
0
0
8
30
2.70
1.73
2.3
2.7
13.82
13.19
%
—
8
30
52
371
1.45
1.68
2.8
2.5
25.25
37.00
u/l
2.00
44
303
25
150
1.71
1.67
2.1
1.7
—
—
—
0
0
63
467
1.41
1.66
2.4
2.8
5.62
8.37
umol/l
1.76
58
418
13
64
2.06
1.55
1.2
1.2
—
—
—
0
0
6
21
2.88
1.51
1.0
1.1
—
—
—
0
0
107
874
1.29
1.50
3.0
2.9
2.48
2.46
mmol/l
1.50
99
787
190
1664
1.25
1.50
5.2
4.0
28.10
72.02
ng/l
0.75
144
1248
314
2912
1.26
1.46
4.8
4.3
15.20
14.90
pmol/l
1.31
293
2631
7
28
2.52
1.45
2.1
1.3
—
—
—
0
0
22
133
1.69
1.45
1.5
1.4
243.40
294.90
ug/g
—
10
76
17
95
1.82
1.45
1.7
1.3
—
—
—
0
0
21
126
1.70
1.42
1.4
1.3
—
—
—
0
0
24
150
1.63
1.41
1.3
4.1
41.69
97.05
mg/l
0.76
18
128
10
46
2.20
1.41
2.1
1.3
—
—
—
0
0
7
29
2.44
1.39
1.0
1.2
—
—
—
0
0
6
23
2.63
1.37
1.0
1.8
—
—
—
0
0
6
23
2.63
1.37
1.0
1.8
—
—
—
0
0
18
105
1.74
1.35
2.7
3.2
0.78
1.85
index
—
9
61
10
47
2.15
1.34
1.1
1.4
27440.00
31297.37
e6/l
—
5
27
9
43
2.12
1.31
3.1
2.0
0.11
0.65
mmol/l
—
9
43
19
114
1.70
1.30
3.1
2.6
1.56
1.59
mg/l
0.05
19
96
32
450
0.69
1.23
14.4
7.8
—
—
—
0
0
63
494
1.32
1.20
1.6
1.5
—
—
—
0
0
6
26
2.32
1.19
7.8
3.6
0.83
1.27
%
—
6
26
89
732
1.27
1.19
1.9
1.8
1083.59
1205.83
nmol/l
0.89
72
557
23
150
1.56
1.17
1.3
4.1
31.06
46.43
mg/l
0.52
17
129
19
118
1.64
1.16
1.4
1.1
—
—
—
0
0
0
35
0.00
1.15
0.0
1.0
—
666.80
—
0
25
0
35
0.00
1.15
0.0
1.1
—
40.52
—
0
24
161
1418
1.21
1.14
4.4
3.3
6.53
7.27
mmol/l
1.96
141
1177
8
41
1.97
1.09
1.6
2.3
—
—
—
0
0
31
222
1.43
1.04
1.5
1.4
—
—
—
0
0
26
180
1.47
1.03
1.3
1.3
—
—
—
0
0
15
91
1.67
1.01
2.9
1.8
3.38
4.69
iu/l
—
8
39
129
1125
1.21
1.00
4.3
3.6
0.23
0.01
estimate
0.57
52
349
360
3444
1.23
0.98
6.1
5.4
1.84
1.99
mu/l
1.61
336
3140
16
100
1.62
0.98
1.4
1.5
—
—
—
0
0
7
37
1.91
0.94
1.0
1.6
—
53.33
—
0
6
6
29
2.08
0.89
1.0
1.2
—
—
—
0
0
10
56
1.80
0.88
1.1
1.0
—
—
—
0
0
262
2453
1.16
0.84
4.0
3.2
76.13
50.89
u/l
1.19
255
2292
197
1808
1.16
0.82
3.4
2.7
—
—
estimate
—
0
0
5
100
0.49
0.78
1.0
1.1
1.60
1.55
g/l
—
5
100
335
3481
0.85
0.76
4.7
4.5
1.21
1.28
mmol/l
1.36
313
3175
353
3652
0.84
0.75
5.7
5.4
4.65
4.59
mmol/l
0.45
335
3374
51
417
1.25
0.75
4.3
3.6
—
—
—
0
0
360
3716
0.84
0.73
6.5
6.2
2.62
2.65
mmol/l
0.26
340
3422
7
39
1.81
0.72
1.3
1.4
—
—
—
0
0
10
60
1.68
0.72
4.3
2.8
105.30
105.53
mmol/l
—
10
60
351
3628
0.85
0.71
5.6
5.3
1.60
1.48
mmol/l
5.30
332
3333
5
26
1.93
0.71
1.0
1.0
—
—
—
0
0
9
59
1.54
0.68
4.7
2.8
1.18
1.19
mmol/l
—
9
59
31
243
1.30
0.64
3.1
2.4
0.64
0.61
%
0.24
31
243
16
112
1.44
0.64
1.6
1.3
—
—
—
0
0
0
21
0.00
0.60
0.0
1.2
—
9.19
—
0
21
0
22
0.00
0.59
0.0
1.2
—
—
—
0
0
171
1584
1.13
0.59
5.2
4.0
0.06
0.03
estimate
0.21
54
361
31
247
1.27
0.58
3.1
2.4
1.13
1.16
%
0.13
31
247
6
36
1.68
0.57
1.2
1.1
—
—
—
0
0
6
39
1.55
0.53
1.2
1.2
—
—
—
0
0
64
558
1.17
0.52
1.6
1.5
—
—
—
0
0
6
98
0.61
0.52
3.7
1.7
52.33
40.77
nmol/l
—
6
92
39
325
1.22
0.52
3.4
2.7
61.16
62.08
ml/min/173m2
0.09
25
134
22
171
1.30
0.51
1.1
1.0
—
—
—
0
0
18
137
1.33
0.48
1.2
3.8
1.40
3.41
ratio
—
10
77
43
502
0.84
0.47
4.7
5.0
35.12
32.39
%
1.07
34
322
55
479
1.17
0.47
3.0
4.4
128.17
40.15
ug/l
0.31
49
400
128
1184
1.11
0.45
5.1
4.2
0.00
0.01
estimate
0.74
53
410
363
3544
1.13
0.43
7.4
6.9
40.28
39.89
mmol/mol
0.34
349
3321
5
33
1.52
0.41
1.2
1.1
—
—
—
0
0
365
3569
1.12
0.40
25.9
17.0
75.93
77.10
ml/min/173m2
0.49
356
3331
64
714
0.88
0.40
3.5
3.2
0.68
0.81
ug/l
0.68
47
463
7
102
0.68
0.40
1.3
1.1
0.83
0.91
g/l
—
7
102
5
35
1.43
0.39
1.2
1.1
—
—
—
0
0
0
19
0.00
0.39
0.0
1.2
—
171.98
—
0
19
149
1404
1.09
0.36
5.2
4.0
4.81
8.41
mg/mmol
1.51
97
853
114
1222
0.91
0.36
5.4
5.6
1.63
2.51
ug/l
2.08
104
1085
44
387
1.15
0.35
1.8
1.8
1.48
1.51
%
0.16
37
333
14
110
1.28
0.32
1.1
1.6
—
—
—
0
0
7
100
0.70
0.31
1.0
1.3
36.23
26.10
iu/l
—
7
86
16
129
1.25
0.30
2.3
2.0
17.66
2.89
mg/l
0.79
16
99
102
953
1.09
0.30
3.4
2.3
—
—
—
0
0
7
55
1.28
0.30
1.0
1.1
—
25.78
—
0
9
7
56
1.25
0.29
6.9
6.5
411.14
357.67
umol/l
—
7
49
15
123
1.23
0.25
1.5
1.3
—
—
—
0
0
11
87
1.27
0.24
3.3
2.0
—
—
—
0
0
18
153
1.18
0.22
2.9
1.5
0.12
0.33
mg/l
—
10
65
357
3620
0.93
0.21
5.5
5.5
5.83
6.03
mmol/l
1.56
334
3311
92
972
0.93
0.21
4.7
4.8
21.77
21.73
%
0.01
42
475
0
11
0.00
0.21
0.0
1.1
—
—
—
0
0
0
11
0.00
0.21
0.0
1.1
—
—
—
0
0
0
11
0.00
0.21
0.0
1.1
—
—
—
0
0
0
11
0.00
0.21
0.0
1.3
—
—
—
0
0
0
11
0.00
0.21
0.0
1.1
—
—
—
0
0
0
10
0.00
0.21
0.0
1.1
—
—
—
0
0
0
10
0.00
0.21
0.0
1.1
—
—
—
0
0
0
10
0.00
0.21
0.0
1.7
—
1.26
—
0
10
39
355
1.11
0.20
2.8
2.5
6.66
7.00
ug/l
0.06
34
314
10
80
1.26
0.20
2.7
2.8
9.87
9.88
pmol/l
—
10
80
13
108
1.21
0.20
3.0
2.0
—
—
—
0
0
167
1614
1.06
0.20
2.2
2.0
1.29
1.32
mmol/l
0.17
139
1350
11
91
1.21
0.17
5.4
2.1
24.82
33.04
umol/l
2.03
11
78
90
865
1.05
0.13
1.7
1.8
420.74
451.11
pmol/l
0.57
78
723
96
928
1.04
0.11
5.7
4.2
1.02
1.02
kg/l
0.56
71
619
6
55
1.09
0.09
1.0
1.6
—
—
—
0
0
11
99
1.11
0.06
1.5
1.7
—
—
—
0
0
22
208
1.06
0.05
2.2
1.8
—
—
—
0
0
10
93
1.08
0.02
1.3
1.4
—
—
—
0
0
23
237
0.97
0.01
1.2
1.2
134.93
137.14
u/ml
0.01
11
92
22
218
1.01
0.00
2.0
3.2
18.18
111.30
u/ml
1.05
22
212
23
229
1.00
0.00
2.6
2.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
1.19
—
0
7
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.5
—
6.94
—
0
8
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint J10_PULMEOS and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| J10_PULMEOS | 1.613 [1.36, 1.91] | < 0.001 |
| Birth year | 0.994 [0.99, 1.0] | 0.183 |
During the follow-up period (1.1.1998 — 31.12.2019), 276 out of 1053 females with J10_PULMEOS died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| J10_PULMEOS | 1.865 [1.56, 2.23] | < 0.001 |
| Birth year | 0.986 [0.98, 1.0] | 0.004 |
During the follow-up period (1.1.1998 — 31.12.2019), 327 out of 857 males with J10_PULMEOS died.
Mortality risk
Mortality risk for people of age
years, who have J10_PULMEOS.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.16% | 0.372% |
| 5 | 0.928% | 2.274% |
| 10 | 2.312% | 5.463% |
| 15 | 4.365% | 9.521% |
| 20 | 7.696% | 15.863% |
Relationships between endpoints
↥Index endpoint: J10_PULMEOS – Pulmonary eosinophilia, not elsewhere classified
GWS hits: 1
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data